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ABSTRACT OF DISSERTATION 
 
 
REGENERATION OF DAMAGED GROWTH PLATE USING IGF-I PLASMID-
RELEASING POROUS PLGA SCAFFOLDS 
Growth plate injuries account for 15-30% of long bone fractures in children. 
About 10% of these result in significant growth disturbances due to formation of a boney 
bar. If not treated correctly, this can lead to life-lasting consequences of limb length 
inequalities and angular deformities. Current treatments for growth plate injuries include 
removal of boney bar and insertion of fat, silicone, bone cement, etc.. This treatment y is 
inadequate, leaving almost half of these patients with continued deformities. This 
dissertation reports characterization of a DNA–containing porous poly(lactic-co-glycolic 
acid) (PLGA) scaffold system, chondrogenesis using insulin-like growth factor I (IGF-I) 
plasmid-releasing scaffolds in vitro, and in vivo testing of IGF-I plasmid-releasing 
scaffolds to regenerate growth plate . Controlled release of naked and DNA complexed 
with polyethylenimine (PEI) was achieved from porous PLGA scaffolds. PEI affected 
release of complexes from PLGA scaffolds, as PEI:DNA complexes were released at a 
lower rate compared to naked DNA encapsulated in low molecular weight (LMW) and 
high molecular weight PLGA scaffolds, as well as hydrophilic and hydrophobic PLGA 
scaffolds. Hydrophilicity and molecular weight of PLGA affected the release profiles of 
both naked DNA and PEI:DNA complexes from the scaffolds, as evidenced by later peak 
DNA and PEI:DNA release with increasing hydrophilicity and molecular weight. LMW 
hydrophilic PLGA scaffolds supported growth and chondrogenic differentiation of 
mesenchymal multipotent D1 cells, chondrocytes, and bone marrow cells (BMCs) in 
vitro. Culturing BMCs on IGF-I plasmid-encapsulated scaffolds resulted in elevated 
expression of IGF-I compared to blank scaffolds. Removal of boney bar and implantation 
of IGF-I plasmid-releasing LMW PLGA scaffolds in a rabbit model of growth plate 
injury resulted in some improvement of leg angular deformity compared to no scaffold 
implantation. Histological analysis of the newly developed cartilage showed growth 
plate-like columnar arrangement of chondrocytes in a defect that received IGF-I plasmid 
 
 
encapsulated scaffold, although the level of organization of newly formed cartilage was 
inferior to that of native growth plate. This appears to be the first report of the 
regeneration of growth plate-like structure without the use of stem cells in an animal 
model of physeal injury. 
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 1 
1. INTRODUCTION 
 
Growth plate injuries account for approximately 15% to 30% of all fractures of 
long bones in children (Mizuta, 1987). About 10% of these will result in significant 
growth disturbances due to the formation of a boney bar (Salter, 1994). This boney bar 
can act as a tether, attaching the epiphyseal bone to the diaphyses, and limiting the 
continued normal growth of the limb. If not treated correctly, this can lead to life lasting 
consequences of limb length inequalities and angular deformities. Current treatments for 
growth plate injuries include removal of boney bar, and insertion of fat, silicone, bone 
cement etc to replace the growth plate. These treatment modalities are inadequate, 
leaving almost half of these patients with continued deformities. 
The current main strategy to regenerate tissue employs biodegradable scaffolds 
with or without progenitor cells and delivery of growth factors that promote the growth 
and differentiation of the target tissue. Different polymer scaffolds made of poly(lactic-
co-glycolic acid) (PLGA) (Munirah, 2008b), hydrogels (Choi, 2007), and chitin (Li 
2004), as well as growth factors as varied as transforming growth factor-β (TGF-β) 
(Choi, 2007), insulin like growth factor-I (IGF-I) (Lee, 2002), connective tissue growth 
factor (CTGF) (Shimo, 2004), and bone morphogenetic factor-2 (BMP-2) (Schmitt, 
2003) have been used for regeneration of tissue. The polymer scaffolds serve as a 
framework for the growth of cells, and can be designed to have degradation rates that 
match the rate of new tissue formation. Delivery of appropriate growth factors from these 
scaffolds can help in recruiting progenitor cells to infiltrate the scaffold, differentiate to 
the right cell type and synthesize the extracellular matrix. Porous PLGA scaffolds have 
been used for controlled delivery of plasmid DNA encoding platelet derived growth 
factor (PDGF), which produced matrix deposition and angiogenesis in developing tissue 
in rats (Shea, 1999). Generating new tissue using a patient’s own cells avoids problems 
with allografts or xenografts, and use of drug-eluting biodegradable scaffolds requires 
only a single surgery to implant the scaffold. 
 But delivery of growth factors from scaffolds comes with its own set of 
problems. The loading and release of the growth factors will have to be precisely 
controlled. The half-life of some growth factors is also extremely small. IGF-I had a half-
life of 240 minutes after injection in rats, while TGF-β1 had a half-life of 60-163 minutes 
(Zapf, 1986; Zioncheck, 1994). This necessitates large initial loading of the delivery 
device with growth factors to last during the entire duration of the treatment. 
Delivery of plasmids coding for the growth factors would be a more efficient 
form of therapy since the synthesis and expression of the factors would now be cell 
mediated. The biological amplification that happens in the DNA to protein synthesis 
pathway will reduce the amount of plasmid DNA that needs to be delivered. Inclusion of 
corresponding regulator genes for the different growth factors can bring their expression 
completely under the control of the cells producing them. This may result in optimal 
levels of growth factor concentrations. The transient transfection that happens after 
plasmid delivery also eliminates concerns of uncontrolled long-term production of 
growth factors. Controlled delivery of plasmids coding for growth factors and their 
regulators can give cell-regulated, short-term expression of therapeutic growth factors. 
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This dissertation reports the DNA release and degradation behavior of a porous 
PLGA scaffold system, chondrogenesis using these scaffolds in vitro, and in vivo testing 
of these scaffolds to regenerate growth plate in a rabbit model of physeal injury. 
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2. BACKGROUND AND SIGNIFICANCE 
 
2.1 Growth plate cartilage: structure and function 
 
The growth plate, or physis, is a narrow layer of cartilage interposed between the 
epiphysis and metaphysis. The epiphysis is the region at the end of long bones that forms 
the articular surface, and the metaphysis is a flared, contoured region of bone that tapers 
into the diaphysis, or shaft of long bones (Beaty). The physis serves to provide 
longitudinal growth for skeletally immature individuals (Ballock). Figure 2.1 illustrates 
the structure of growth plate. 
 The primary cell type found in all cartilage is called a chondrocyte. Chondrocytes 
are predominantly round cells located within spaces in cartilage called lacunae (Lin, 
2006). They arise from pluripotent mesenchymal stem cells through a series of 
differentiation steps (Lin, 2006). Chondrocytes synthesize extracellular proteins, the most 
abundant being type II collagen, as well as chondroitin sulfate proteoglycans, such as 
aggrecan (Lin, 2006). The string-like collagen molecules give cartilage primarily its 
tensile strength, while aggrecan and the water molecules associated with it give cartilage 
its compressive strength (Knudson, 2001). Aggrecan monomers are made of a core 
protein and keratin sulfate glycosaminoglycan chains, and fill up the interstices among 
the collagen network by interacting with hyaluronic acid molecules and link proteins 
(Nagase, 2003). 
Physeal cartilage has several anatomic layers. The resting zone lies closest to the 
epiphyseal region. It contains chondrocytes in a relatively quiescent state, and there is a 
high ratio of extracellular matrix (ECM) to cell volume. The ECM consists mostly of 
Type II collagen and proteoglycans with aggrecan being the most abundant.  
Chondrocytes in this layer store lipids, glycogen, and proteoglycans. The proliferative 
zone is the main site for longitudinal growth. As the chondrocytes proliferate they 
become flattened in appearance and stack into columns. There is increased proteoglycan 
and ECM synthesis, and this helps prohibit calcification. In the hypertrophic zone, cells 
increase fivefold to tenfold in size and begin to terminally differentiate. This zone is 
sometimes divided into three zones: maturation, degeneration, and provisional zone of 
calcification (Ballock).  
 The periphery of the physis contains two distinct elements. The groove of Ranvier 
is a wedge-shaped region of chondrocyte progenitor cells that contributes reserve zone 
cells. This contributes to lateral growth of the physis allowing growth in width as well as 
length. A peripheral ring of fibrocartilage surrounds and overlies the groove of Ranvier. 
Known as the perichondrial ring of LaCroix, this fibrous band merges with the 
periosteum and provides mechanical support and an anchoring membrane to the 
periphery of the physis (Beaty; Ballock).  
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Figure 2.1 Illustration of growth plate 
 
2.2 Cartilage development 
Chondrogenesis is a multistep process that begins with the recruitment of 
mesenchymal progenitor cells. The recruitment, proliferation and condensation of 
mesenchymal cells are regulated by mesenchymal-epithelial cell interactions (Tuan, 
2004; Hall, 2000). The aggregation of chondroprogenitor mesenchymal cells is one of the 
earliest events in chondrogenesis (Goldring, 2006). Limb buds form from the lateral plate 
mesoderm (Tickle, 2001). Genes than pattern mesenchymal condensation operate in a 
sequential manner to form limb buds (Tickle, 2003). TGF-β is one of the earliest of the 
growth factors that stimulate chondrogenic condensation (Goldring, 2006). Extracellular 
molecules in the matrix interact with cell adhesion molecules to convert the chondrogenic 
progenitors to fully committed chondrocytes (DeLise, 2000). BMPs are involved in the 
maturation of chondrocytes and terminal differentiation later into hypertrophic 
chondrocytes (Goldring, 2006). The differentiation of chondroprogenitors leads to further 
stages of skeletogenesis, and is marked by the production of Collagen II, IX and XI, and 
aggrecan (Goldring, 2006). Balance of signaling between BMPs and fibroblast growth 
factors (FGFs) determines the rate of proliferation, and thus differentiation of 
chondrocytes (Minima, 2002). Chondrocytes express a program driven by SOX9, Runx2 
and other transcription factors (Kronenberg, 2003). SOX9, expressed by proliferating but 
not hypertrophic chondrocytes, is essential for every stage of chondrocytes 
differentiation, and stimulates transcription of multiple cartilage matrix genes such as 
Resting zone 
Proliferative 
zone 
Hypertrophic 
zone 
Metaphyseal 
zone 
Chondrocytes 
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Col2a1, Col11a2 and aggrecan (Kronenberg, 2003). Runx2 is a transcription factor 
important in the transformation of proliferative chondrocytes to hypertrophic 
chondrocytes (Kronenberg, 2003). The activities of different transcription factors, and 
their differential expression in different chondrocytes give an indication of the complex 
physiology in chondrocyte development. 
 
2.3 Growth plate development 
As described in section 2.1, growth plate has three regions: the resting zone, 
proliferative zone and hypertrophic zone. The chondroblasts in the resting zone are small 
in size and inactive. As they become active and differentiate, they move into the 
proliferative zone and start to synthesize matrix proteins (Van der Eerden, 2003). These 
chondrocytes then become hypertrophic and synthesize collagen X which allows 
mineralization of the extracellular matrix (Wit, 2003). At the growth plate-metaphyseal 
junction hypertrophic chondrocytes die by apoptosis, paving the way for invasion of 
blood vessels into the calcified zone (Chung, 2006).  Proliferation of chondrocytes in the 
embryonic and post-natal growth plate is regulated by multiple FGFs that act on the 
cyclin D1 gene (Beier, 2005). Chondrocytes in the proliferative and prehypertrophic zone 
are controlled by a negative feedback loop involving parathyroid hormone-related protein 
(PTHrP) and Indian hedgehog (Goldring, 2006). Indian hedgehog, which is synthesized 
by chondrocytes, regulates bone development by coordinating chondrocyte 
differentiation (Kronenberg, 2003). PTHrP is synthesized by perichondrial cells and acts 
on proliferative chondrocytes to keep them in the proliferative pool (Kronenberg, 2003). 
Extracellular matrix proteins such as osteocalcin and osteopontin are thought to be 
involved in endochondral ossification (Goldring, 2006). Upregulation of the Cadherin-11 
gene has been shown to be one of the factors involved in the process of growth plate 
calcification (Matsusaki, 2006). Extracellular matrix remodeling might be the rate 
limiting factor in the chain of events that occurs during endochondral ossification 
(Ortega, 2004). The angiogenic factor vascular endothelial growth factor (VEGF) 
promotes the invasion of blood vessels into cartilage, which is essential for the 
replacement of cartilage by bone (Colnot, 2001; Colnot, 2005). VEGF is released from 
the matrix by matrix metalloproteases expressed by endothelial cells (Goldring, 2006). 
These blood vessels bring osteoblasts and osteoclasts, which remodel the calcified 
cartilage into metaphyseal trabecular bone (Chung, 2006). 
It has been postulated that a gradient of BMPs across the growth plate might be 
responsible for maintaining different phenotypes of chondrocytes in different zones of the 
growth plate (Nilsson, 2007). It was found that BMP-2 and BMP-6 were upregulated in 
the hypertrophic zone, while growth and differentiation factor-10 (GDF-10) and BMP-7 
were upregulated in the proliferative zone (Nilsson, 2007). Chondrocytes in the resting 
zone and proliferative zone respond differently to BMP-2, with resting zone chondrocytes 
increasing DNA synthesis and higher alkaline phosphatase activity in response to BMP-2 
(Erickson, 1997). Differential expression of genes in different zones of the growth plate 
has been reported. Genes Fmod, Prelp, Ldha and Eno1 were expressed more in the 
proliferative zone, while MMP13 and Col1a1 were expressed more in the hypertrophic 
zone (Wang, 2004). Of the 40 genes that were differentially expressed in the proliferative 
zone of rat growth plate, 8% had cell cycle regulatory functions, while this was 0% 
among the 52 genes that were differentially expressed in the hypertrophic zone (Wang, 
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2004). This shows that chondrocytes in different zones of growth plate respond 
differently to growth factors and express different proteins according to their 
physiological role in the growth plate. 
 In addition to the autocrine and paracrine regulation of growth plate by growth 
factors, hormones play an endocrine role in growth plate physiology. It has been shown 
that decreasing levels of thyroid hormone or growth hormone as well as increasing levels 
of glucocorticoids can act on growth plate, resulting in slower growth rate (Nilsson, 
2005). The dual effector hypothesis on growth hormone states that growth hormone acts 
directly at the growth plate to recruit resting chondrocytes into proliferation as well as 
stimulation of IGF-I production, which in turn leads to proliferation of proliferative zone 
chondrocytes (Ohlsson, 1992; Isaksson, 1987). Glucocorticoid receptors are expressed by 
growth plate chondrocytes (Silvestrini, 2000). In fetal mouse tibia, thyroid hormone 
promotes longitudinal growth by stimulating the hypertrophic zone (Miura, 2002). It has 
been shown that resting zone chondrocytes respond primarily to the 24,25-(OH)2D3 
metabolite of Vitamin D, while growth zone chondrocytes respond primarily to the 1,25-
(OH)2D3 metabolite (Boyan, 1988). Indirect evidence has suggested that epiphyseal 
fusion occurs when the proliferative capacity of the growth plate chondrocytes are 
exhausted, and that estrogen can hasten the onset of this event (Weise, 2001). Aromatase 
is expressed in the human growth plate cartilage, thus allowing androgens to influence 
growth by its conversion to estrogen (Oz, 2001). 
 
2.4 Growth plate injuries 
The physis is a unique component of skeletally immature bone. This thin layer of 
cartilage is susceptible to fracture under mechanical stress or loads that may result in 
metaphyseal or articular fractures in adults. The physis can be damaged by trauma as well 
as due to infection, tumors, or vascular insults (Beaty). As the region responsible for 
longitudinal growth in long bones, damage to the physis may result in growth 
abnormalities. 
 Fractures resulting in physeal injury are relatively common. The incidence varies 
in studies from 14.5% to 27.6%. Combining the results of multiple studies revealed 1,404 
physeal injuries in 6,479 fractures for an overall average incidence of 21.7% (Beaty). 
There are several classification systems for fractures involving the physis. The most well 
known and commonly used is the Salter-Harris classification (Salter, 1963) (Figure 2.2). 
This classification involves five types. Type I is a fracture through the physis that is 
limited to or contained within the physis. Type II fractures extend from the physis into 
the metaphysis. In type III fractures, the fracture extends from the physis into the 
epiphysis and most frequently involves the articular surface. Type IV fractures involve 
extension of the fracture line through the metaphysis as well as the epiphysis and the 
articular surface. Type V fractures are defined as a crush injury to the physis. By 
definition, on initial presentation there is no radiographic abnormality, but these patients 
will experience premature physeal closure at the region of injury. 
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Figure 2.2 The Salter-Harris classification of physeal fractures 
 
One of the unique complications of physeal fractures is partial growth arrest that 
results from the formation of a boney bar or bridge that connects the epiphysis to the 
metaphysis creating a tether. This tethering may result in uneven growth at the physis and 
subsequent angular limb deformity, leg length discrepancy, and joint abnormalities. 
Partial growth arrest is not very common, with significant growth disturbances occurring 
in approximately 10% of physeal injuries (Salter, 1994). It is found to occur most often in 
Salter-Harris types III and IV fractures. These fractures significantly disrupt the resting 
and proliferative zones of the physis, and this is suspected to increase the chance of 
boney bar formation. Salter-Harris type IV fractures are often significantly displaced 
allowing the metaphysis and epiphysis to come in contact and further increasing the risk 
of formation of a boney bridge tether. The physes of the distal femur and proximal tibia 
are those most at risk for this phenomenon (Beaty). 
 
2.5 Chondrogenic growth factors 
The majority of studies on cartilage regeneration have focused on regenerating 
damaged articular cartilage. Various growth factors such as IGF-1, TGF-β, FGF-2, BMPs 
and CTGF have been studied by different investigators for their chondrogenic potential. 
 Connective tissue growth factor belongs to a family of genes called 
ctgf/cyr61/nov (CCN) (Moussad, 2000). CTGF, a growth factor specific to hypertrophic 
growth plate chondrocytes, has been shown to enhance proliferation, maturation and 
hypertrophy of growth plate chondrocytes (Nakanishi, 2000). It also increased cell 
proliferation and production of aggrecan and collagen X when administered to 
chondrocytic cells (Nakanishi, 2000b). Treatment of auricular chondrocytes with 
rhCTGF significantly increased elastin and collagen-II mRNA, while also increasing the 
expression of matrix gla protein (MGP), an inhibitor of mineralization (Fujisawa, 2008). 
When micromass cultures were stimulated with CTGF, it resulted in chondrogenic 
differentiation (Shimo, 2004).  
Adult canine chondrocytes cultured on a collagen scaffold with the addition of 
FGF-2 were shown to have a significant increase of GAG content (Veilleux, 2005). 
Interestingly, the combination of IGF-1 and FGF-2 led to an even higher GAG content 
compared to groups that received either growth factor alone (Veilleux, 2005). FGF-2 has 
also been shown to increase chondrocyte proliferation, but decrease the anabolic effect of 
IGF-1 and osteogenic protein 1 (OP-1) on articular chondrocytes cultured in alginate 
beads (Loeser, 2005). In a monolayer culture of human nasal septal chondrocytes, FGF-2, 
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along with TGF-β, was found to have the greatest effect on cell proliferation, but these 
cells took a fibroblast-like morphology (Richmon, 2005).  
Growth and differentiation factor-5 (GDF-5) is a member of the TGF-β 
superfamily. It has been shown to increase chondrogenesis in vitro in a dose dependent 
manner, and increase the size of early cartilage condensation and skeletal elements in 
vivo (Francis-West, 1999). Addition of GDF-5 to mouse mesenchymal cells increased 
cell proliferation, mesenchymal condensations and cartilage nodule formation in vitro 
(Hatakeyama, 2004). This also led to increased expression of Col2a1, probably mediated 
through Sox9 (Hatakeyama, 2004). 
Ectopic bone formation after demineralized bone matrix was injected into muscle 
compartments led to the discovery of the potent growth factor BMP (Urist, 1965). BMPs 
can induce osteogenic or chondrogenic differentiation of mesenchymal stem cells 
depending on the BMP isoform, dosage and origin of the cells (Mehlhorn, 2007). BMP-2 
has been shown to induce an osteogenic phenotype in periosteum-derived progenitor cells 
(Iwasaki, 1994), while inducing chondrogenic phenotype in adult human mesenchymal 
stem cells (Schmitt, 2003). Low concentration of BMPs have been shown to induce 
differentiation of embryonic and mesenchymal cells to adipocytes, while high 
concentration induces differentiation into osteoblasts (Granjeiro, 2005). Alginate culture 
of human adipose-derived stem cells resulted in significantly higher GAG production and 
Col2a1and cartilage oligomeric matrix protein (COMP) mRNA production when treated 
with a combination of BMP-2 and TGF-β (Mehlhorn, 2007). BMP-4 and GDF-5 are 
closely related proteins and even share some receptors (Hatakeyama, 2004). Addition of 
BMP-4 to mesenchymal cell micromass culture has been shown to induce cartilage 
formation and maturation (Hatakeyama, 2004). Sekiya et al compared the effect of BMP-
2, -4 and -6 on in vitro cartilage formation of adult human bone marrow stromal cells. 
BMP-2 was found to be the most effective, producing most cartilage matrix compared to 
BMP-4 and -6 (Sekiya, 2005). 
IGFs are single chain polypeptide growth factors, and are expressed in a wide 
variety of cell types where they act as cellular growth factors (Kleffens, 1998). IGF-I and 
IGF-II both exert their effects through type-I IGF receptor (Kleffens, 1998). IGFs are 
bound in the extracellular compartment and in circulation by IGF binding proteins, which 
have comparable affinities for IGFs as their receptors (Kleffens, 1998). IGF binding 
proteins are thought to modulate the function of IGF by increasing or decreasing the 
availability of IGF (Jones, 1995). IGF-I can induce the formation of limb buds from 
prospective limb regions (Dealy, 1996). IGF-I has been shown to be expressed in regions 
undergoing precartilage condensation from mesoderm in mouse limb development 
(Kleffens, 1998). Combination of IGF-I and osteogenic protein 1/ (BMP-7) treatment 
produced significantly higher cell survival and matrix synthesis in osteoarthritic and 
normal human articular chondrocytes cultured in alginate beads (Loeser, 2003). 
Histological analysis of repair tissue after delivery of IGF-I gene using adenoviral vector 
to full thickness chondral defects was shown to increase aggrecan and collagen-II content 
in horses (Morisset, 2007). Transplantation of chondrocytes genetically altered to 
produce IGF-1 into an equine cartilage defect repair model resulted in significantly 
higher collagen-II content and gross filling of defects compared to untreated defects 
(Goodrich, 2007). Culturing human mesenchymal stem cells on IGF-1 loaded silk fibroin 
scaffolds have been shown to produce significantly higher GAG deposition compared to 
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unloaded silk fibroin scaffolds (Uebersax, 2008). Delivery of IGF-1 from a degradable 
hydrogel scaffold resulted in some cartilage regeneration in a rabbit osteochondral defect 
model (Holland, 2007). Interestingly, combination of IGF-1 and TGF-β did not result in 
any improvement over IGF-1 delivery alone, and delivery of TGF-β alone showed 
excessive tissue growth (Holland, 2007). IGF-1 was useful in maintaining the round 
morphology of humans nasal septal chondrocytes when grown as monolayer culture, and 
increased their proliferation (Richmon, 2005). Treatment of full thickness cartilage 
defects in horses with IGF-1 laden fibrin clots resulted in better tissue filling, more 
columnar cellular organization, and significantly higher collagen II content compared to 
untreated defects (Nixon, 1999). Similar results were seen when IGF-I laden 
chondrocyte-fibrin suspension, compared to chondrocytes-fibrin suspension was used to 
treat full thickness defects in horses (Fortier, 2002). Transplantation of alginate 
encapsulated chondrocytes overexpressing IGF-1 improved articular cartilage repair in a 
lapine model of osteochondral defect (Madry, 2005).  
 
2.6 Gene delivery 
A medical intervention designed to treat human diseases by correcting genetic 
deficiencies or by producing therapeutic proteins is called somatic cell gene therapy 
(Kupfer). The targeted organ becomes an “in situ factory” for the release of a therapeutic 
agent as the host cell uses its own regulatory machinery to control production and 
secretion of recombinant protein, (Kupfer). The first report of mammalian gene transfer 
appeared in 1980, when methotrexate-susceptible murine bone marrow cells were 
transformed into drug-resistant cells by the introduction of the gene for dihydrofolate 
reductase, a protein capable of metabolizing methotrexate (Cline, 1980). 
Gene therapy involves five consecutive steps: delivery of DNA to target cells, 
cellular internalization, nuclear translocation, transcription and translation, and protein 
processing (Kupfer). Cellular uptake and nuclear translocation of naked DNA are 
difficult because of the large size of naked DNA. Plasmid DNA exhibits low transfection 
efficiency in vivo because of enzymatic degradation, chemical instability, and 
macrophage uptake (Mahato, 1999). Carrier molecules increase the transfection 
efficiency by efficiently delivering DNA to the interior of cells. 
 
2.6.1 Carriers for gene therapy 
Liposomes: Liposomes are small, non-toxic, biodegradable vesicles composed of 
a phospholipid bilayer (Wightman). A cationic lipid is a positively charged molecule with 
a hydrophilic head and a hydrophobic tail that self-associates in aqueous solution to form 
either micelles or bilayer liposomes (Wightman). Liposome-mediated gene delivery is 
based on the concept that the phospholipid composition would facilitate delivery of 
macromolecules by promoting membrane fusion. Preparation of liposomes is time 
consuming and employs organic solvents. Encapsulation efficiency using liposomes is 
variable and dependent on lipid composition and the method of preparation (Kupfer). 
Liposomes are also unstable in aqueous solutions and can have membrane-induced 
leakage.  
Retrovirus: These viruses are exclusively of murine origin, and have been used 
as vectors in human gene therapy. Their ability to integrate and permanently alter the host 
genome carries the risk of producing cancer or mutations (Kupfer). 
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Adenovirus: Human adenovirus is not associated with malignant transformations 
in humans, as they have no mechanism for inserting their DNA into the host cell 
chromosome. They have high transfection efficiency and can be easily propagated 
(Kupfer). The greatest limitations to adenovirus mediated gene transfer are the 
immunogenic response to viral proteins and the transient nature of recombinant gene 
expression. 
Immune response to the viral particles and their proteins, and safety concerns 
have limited the acceptability of viral vectors for gene delivery. 
Chemical vectors: Chemical vectors are attractive to the pharmaceutical industry 
as alternatives to viral vectors because of compound stability and easy chemical 
modification (Wightman). Better biosafety, consistency of production, and low cost of 
these chemicals make them attractive candidates for gene delivery. Several polymeric 
molecules have been developed that can interact with the negatively charged phosphate 
groups in naked DNA, condense it into compact particles, protect it from degradation, 
and enhance the uptake of DNA into the cell resulting in efficient transgene expression 
(Wightman).  
 
2.6.1.1 Polyethylenimine (PEI) 
Polyethylenimines are positively charged polymers that are available in molecular 
weights ranging from 200 to 800,000 Da and in linear or branched form (Bieber, 2002). 
They are positively charged due to the large number of amine groups, which makes them 
suitable to condense the negatively charged DNA and facilitate their entry into cells 
(Bieber, 2002; Clamme, 2003). PEI has proved to be a highly effective non-viral vector 
for delivering plasmid DNA (Boussif, 1995). PEI interacts electrostatically with the 
phosphate groups of DNA via its protonated amine groups, creating a condensed particle 
called a polyplex (Wightman). The condensation of the PEI around the DNA protects it 
from nuclease activity within the cell. It also enhances cellular uptake of the condensed 
DNA by interacting with the negatively charged cell surface proteoglycans.  
The extent of condensation between PEI and DNA will depend on the ratio of 
nitrogen atoms in PEI to phosphorus in DNA. PEI has been shown to efficiently 
condense and deliver large DNA up to 2.3 Mbp (Baker, 1997). PEI-DNA complexes are 
taken up by the cell, and the endosome is acidified, where the PEI acts as a proton sponge 
(Wightman). It is thought that the interaction of PEI amines with protons triggers osmotic 
swelling of the complex, causing the endosome to rupture and thus release the complexes 
into the cytoplasm (Wightman). Systemically delivered PEI-DNA complexes resulted in 
high gene expression in the lungs of mice (Goula, 1998). 
The branched form of PEI is produced by cationic polymerization of aziridine 
monomers, while the linear form is produced by cationic polymerization of 2-substituted 
2-oxazoline monomer (Godbey, 1999). Figure 2.3 shows the structure of branched PEI. 
The basic unit of branched PEI has a backbone of two carbons followed by a nitrogen 
atom. The branched form of PEI has 1º, 2º, 3º amines which can be protonated under 
physiological conditions. 
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Figure 2.3 Structure of branched PEI (Adapted from Godbey, 1999) 
 
In sufficient amounts, PEI can condense DNA by electrostatic interaction. The 
shape of the PEI:DNA condensate can take various forms and may be more a function of 
the kinetics behind the condensation than the particular form of PEI used (Godbey, 
1999). The size of the PEI:DNA complex was found to be between 20nm and 40nm using 
atomic force microscopy (Dunlap, 1997), and between 90nm and 130 nm in solution 
using dynamic light scattering (Tang M, 1997).  
 
2.7 Controlled delivery 
Controlled delivery refers to the release of a substance in a predictable and precise 
manner from a carrier. Drug carriers can release their contents passively into their 
environment by two main methods: diffusion or degradation. The simpler of these two 
methods is a diffusive process where the drug is released from its carrier down its 
concentration gradient. Diffusion can be time independent or time dependent (Crank, 
1968; Hopfenburg, 1969). When the carrier matrix reaches equilibrium with a solvent 
slower than the solvent reaching the solvent front during swelling, time independent 
diffusion occurs (Brannon-Peppas, 1989). On the other hand, if the carrier swells to 
equilibrium faster than the solvent reaching the solvent front, time dependent diffusion 
occurs (Brazel, 1999). In degradation controlled release, delivery of the drug is 
determined by the degradation kinetics of the carrier material (Langer, 1998). 
Degradation controlled release can also occur if the drug molecule is bound chemically or 
physically to the polymer molecule, and when the drug molecules are physically larger 
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than the pore size of the polymer carrier (Dihayat, 1993; Langer, 1998). Most controlled 
delivery devices have a combination of these processes occurring at the same time.  
Release profiles usually have an initial “burst” immediately following the 
immersion of the delivery device in solvent. This is caused by release of drugs loosely 
bound or adsorbed onto the surface of the device (Hora, 1990). The initial burst release is 
followed by a diffusion controlled phase. Degradable devices then enter a third phase of 
degradation controlled release (Hora, 1990). During this phase, the device loses its 
mechanical integrity leading to release of drug into the solvent. These three phases 
together form a “triphasic release profile” (Hora, 1990).  
 
2.7.1 DNA release from polymeric matrices 
Various polymeric carriers have been investigated for the controlled release of 
naked DNA and PEI:DNA polyplexes. DNA-polycation nanospheres made by salt-
induced coacervation of DNA and gelatin was used to transfect a variety of cell lines 
(Leong, 1998; Truong-Le, 1999). Plasmid genes were released from three-dimensional 
poly(lactic-co-glycolic) (PLGA) matrices with different degradation rates (Shea, 1999). 
The release rate from the PLGA polymeric matrix was controlled by changing the 
molecular weight of the polymer and diameter of the microspheres used to make the 
scaffolds (Jang, 2003). Amine derivatives of gelatin were used for release of plasmid 
genes to gastric mucosal cells in vitro (Hosseinkhani, 2002). Microspheres of PLGA were 
used to encapsulate polylysine-complexed DNA and successful transfection in vitro 
(Gebrekidan, 2000). Freeze-dried PEI:DNA complexes were mixed with granular PLGA 
and compression molded to create a DNA delivery device (Huang, 2003). An injectable 
in-situ formed gene delivery system using PLGA dissolved in glycofurol was 
successfully tested in rats (Eliaz, 2002). 
 
2.8 Biodegradable polymers. 
In this study, “biodegradable” refers to a polymer that can be converted to water-
soluble material by a combination of physical and chemical processes. Although 
biodegradable materials are not designed to be permanently implanted in the body, they 
actually have to meet stringent conditions of biocompatibility because the degradation 
products of the material also have to be non-toxic and biocompatible with the host body. 
Very few polymers have found use as biodegradable polymer for implantation because of 
this restriction.  
After exposure to the physiological environment a biodegradable polymer can 
degrade by surface erosion and bulk erosion. In bulk erosion, the degradation process 
takes place throughout the entire volume of the polymer after the intake of water. The 
rate at which water penetrates into the polymer matrix exceeds the rate at which the 
polymer transforms into water-soluble materials during bulk erosion (Heller, 1987). In 
surface erosion, degradation of the polymer is limited to the outer surface of the device 
(Heller, 1987). The rate at which water penetrates into the polymer matrix is slower than 
the rate at which the polymer is converted into water-soluble materials during bulk 
erosion (Heller, 1987). The device will therefore become thinner with time as the 
polymer is degraded from its surface. The polymer has to be hydrophobic to a certain 
extent in order for surface erosion to occur (Heller, 1987).  
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2.8.1 Types of Biodegradable polymers 
Polyesters 
Poly(lactic acid), poly(glycolic acid), and PLGA belong to a class of polymers 
called aliphatic polyesters (Agrawal, 2001). Nonspecific hydrolysis of ester linkages, 
which breaks polymer chains into shorter chains is the primary degradation mechanism of 
this type of polymers (Lewis, 1990). PLA-PGA materials have been widely used in 
musculoskeletal tissue engineering applications (Agrawal, 2001). 
Polyanhydrides 
The surface eroding property of polyanhydrides have made them attractive 
candidates for drug delivery applications (Agrawal, 2001). They are sensitive to 
hydrolysis and degrade rapidly (Agrawal, 2001). Aliphatic polyanhydrides degrade 
within days while aromatic anhydrides can take years to degrade, resulting in the 
development of copolymers with intermediate rate of degradation (Ratner). An example 
of polyanhydride is poly (sebacic acid-hexadecanoic acid anhydride). 
Polyorthoesters 
This surface eroding class of polymers also find applications in drug delivery 
(Agrawal, 2001). However, they have the disadvantage of mechanical weakness, limiting 
their applications in musculoskeletal applications (Agrawal, 2001). An example of 
polyorthoester polymer is 3,9-bis(ethylidene 2,4,8,10-tetraoxaspiro[5,5] undecane):trans-
cyclohexane dimethanol:1,6-hexanediol (Ratner). 
Polycaprolactones 
These are also polyesters related to PLA and PGA, but with a slower degradation 
rate (Agrawal, 2001). They find applications as drug delivery devices as well as 
degradable staples for wound closure (Ratner).  An example of this class of polymer is 
poly(є-caprolactone) (Ratner). 
Polycarbonates 
Poly(bisphenol A-iminocarbonate) is a hydrolytically degradable polycarbonate 
that has good mechanical properties and biocompatibility (Agrawal, 2001). 
Poly(bisphenol A-iminocarbonate) are also called pseudo-poly(amino acids), and have 
the potential to be orthopedic biomaterials (Agrawal, 2001). 
Polyfumarates 
These are partially saturated linear polyesters with mechanical properties similar 
to that of trabecular bone (Agrawal, 2001). They have the ability to cure in vivo, making 
them ideal candidates for injectable scaffolds (Agrawal, 2001). An example of this class 
of polymer is poly(propylene fumarate).  
 
2.8.2 Poly(lactic-co-glycolic Acid) PLGA 
PLGA is a copolymer of lactic acid and glycolic acid. Its close analog PLA has 
found medical applications for over 30 years, mostly as an orthopedic biomaterial. PLGA 
has proven to be a versatile vehicle for drug delivery as PLGA devices have been used in 
hard tissue and soft tissue applications, and load bearing as well as non-load bearing 
applications (Athanasiou, 1996; An, 2000; Quereshy, 2000). PLGA has been fabricated 
into different physical forms such as thin films (Grizzi, 1995), microspheres (Witt, 2001; 
Park, 1998), foams (Lu, 2000), surface coatings (Price, 1996) and rods (Sendil, 2002). 
PLGA has been used to deliver hormones (Wei, 2004; Capan, 2003) as well as growth 
factors (Shea, 1999). 
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PLGA microspheres were used for controlled delivery of parathyroid hormone to 
osteosarcoma cells in vitro, and stimulated increased serum calcium levels in vivo (Wei, 
2004). Porous PLGA scaffolds have been used for controlled delivery of plasmid DNA 
encoding PDGF, which produced matrix deposition and angiogenesis in developing 
tissue in rats (Shea, 1999). PLGA-surface adsorbed PEI:DNA complexes have been used 
for transfecting cells in-vitro, where similar transfection efficiency as bolus DNA 
delivery was seen with orders of magnitude less DNA (Jang, 2006). Porous PLGA 
scaffold with encapsulated PEI:DNA particles showed higher transfection in vivo, 
compared to bolus or plasmid delivery of DNA (Huang, 2005). This gene expression was 
seen up to 15 weeks, and at that time point the expression levels were nearly two orders 
of magnitude higher than controls (Huang, 2005). Delivery of PEI:DNA particles with 
DNA encoding BMP-4 from PLGA scaffolds resulted in significant bone regeneration in 
a rat cranial defect model (Huang, 2005b). PLGA microspheres have been used for 
intramuscular gene delivery, where the expression increased up to three months and 
continued until 6 months after microsphere injection (Jang, 2006b). Culturing human 
bone marrow stromal cells on PLGA sutures with the addition of TGF-β, and GDF-5 to a 
lesser extent, led to the production of collagenous tissue (Jenner, 2007). PLGA 
microspheres have also been used for controlled release of polylysine complexed DNA 
(Gebrekidan, 2000). Sustained release of BMP-2 from a PLGA device led to 75% healing 
of a rabbit calvarial defect, compared to 45% healing when the release was immediate 
(Woo, 2001). PLGA scaffolds can be made to release growth factors sequentially, a 
desirable feature since wound healing involves multiple growth factors acting in 
synchrony. Sequential delivery of TGF-β and IGF-I for 70 days have been achieved from 
PLGA scaffolds (Jaklenec, 2008). PLGA devices have also been used in combination 
with other polymers to enhance or alter the release profiles and cell response to these 
devices.  
A hybrid scaffold using fibrin and PLGA scaffold has been shown to accelerate 
chondrogenesis using articular chondrocytes, as evidenced by GAG production, and 
intense safranin-O staining (Munirah, 2008). Implantation of similar scaffolds 
subcutaneously in mice resulted in cartilaginous tissue formation, with significantly 
higher GAG content compared to PLGA scaffolds at 2 weeks (Munirah, 2008b).  
 
2.8.2.1 Mechanism of hydrolysis of PLGA 
Hydrolysis is the cleavage of susceptible bonds by reacting with water. It can be 
catalyzed by acids, bases, salts or enzymes (Ratner). Hydrolysis is a single step process in 
which the rate of chain scission is directly proportional to the rate of initiation of the 
reaction (Schnabel, 1981). The rate of hydrolysis tends to increase with a high proportion 
of hydrolysable groups in the main or side chain, other polar groups that enhance 
hydrophilicity, low crystallinity, cross-link density, and a high ratio of exposed surface 
area to volume (Ratner). PLGA undergoes degradation by hydrolysis. The rate limiting 
step in the hydrolysis of PLGA is the nuclueophilic addition of water to the ester carbon 
by an SN2 mechanism (Raiche diss). Chain scission occurs throughout the PLGA device 
until the oligomers formed are 8-10 monomers long, at which point they are soluble in 
water. Drug within the PLGA device is released in a diffusion controlled manner until the 
PLGA oligomers are of soluble length. Once the oligomers become soluble in water, the 
drug within PLGA is released by degradation (Raiche diss). 
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The bulk eroding property of PLGA means that device geometry is ineffective in 
controlling the release profile of the encapsulated drug. Two methods that can be 
employed to alter the release profiles are: changing the molecular weight of the polymer, 
and changing the hydrophilicity of the polymer molecule.  
 
2.9 Current state-of-art and limitations 
For all the positive results seen with the delivery of growth factors, this approach 
is also fraught with pitfalls. The effects of growth factors are highly dose dependent. 
TGF-β has shown negative effects with high doses (Fujimoto, 1999; Terell, 1993). The 
loading and release of the growth factors will thus have to be precisely controlled. The 
half- life of some of the growth factors is also extremely small. IGF-1 had a half-life of 
240 minutes after injection in rats, while TGF-β1 had a half-life of 60-163 minutes (Zapf, 
1986; Zioncheck, 1994). This necessitates large initial loading of the delivery device with 
growth factors to last during the entire duration of the treatment. 
Delivery of plasmids coding for the growth factors would be a more efficient 
form of therapy since the synthesis and expression of the factors would now be cell 
mediated. Genes encoding FGF delivered from a gelatin-collagen admixture into muscle 
wounds resulted in tissue repair (Doukas, 2002). More importantly, recombinant human 
FGF delivered from the gelatin-collagen admixture failed to produce the same response 
(Doukas, 2002). Direct transfer of genes coding for BMP-4 and parathyroid hormone 
fragment from a collagen sponge resulted in new bone formation in adult rats (Fang, 
1996). 
The biological amplification that happens in the DNA to protein synthesis 
pathway will reduce the amount of plasmid DNA that needs to be delivered. Inclusion of 
corresponding regulator genes for the different growth factors will bring their expression 
completely under the control of the cells producing them. The transient transfection that 
happens after plasmid delivery also eliminates concerns of uncontrolled long-term 
production of growth factors. Controlled delivery of plasmids coding for growth factors 
and their regulators can give cell-regulated, short-term expression of therapeutic growth 
factors.  
 
2.10 Objectives and hypotheses 
The objectives of these studies were to develop a biodegradable polymer scaffold 
that could release a plasmid encoding a chondrogenic growth factor, in a controlled 
manner, and would be able to regenerate damaged growth plate in an animal model of 
growth plate injury. The hypotheses were that such scaffolds would be able to induce 
chondrocytic differentiation in vitro of mesenchymal precursor cells seeded on them, and 
would also regenerate growth plate-like structures when implanted in animals that had 
damaged growth plates. To test these hypotheses, we developed porous scaffold using 
PLGA polymer that released naked and PEI complexed plasmid DNA in a controlled 
manner. We tested the polymer scaffolds in vitro by culturing mesenchymal precursor 
cells on these scaffolds in the presence of a known chondrogenic factor, IGF-I, and 
analyzing their proliferation and cartilage matrix synthesis. Finally, we implanted blank 
and IGF-I plasmid releasing scaffolds in an animal model of growth plate injury and 
histologically and morphometrically analyzed the success in reversing the damaging 
effects of growth plate injury. 
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3. CONTROLLED RELEASE OF NAKED AND PEI-COMPLEXED DNA FROM 
POROUS PLGA SCAFFOLDS 
 
3.1 INTRODUCTION 
The ability to precisely control the delivery of single or multiple bioactive 
molecules is critical in tissue engineering, as tissue formation involves the interplay of 
multiple growth factors and signaling molecules. Biodegradable microspheres and porous 
scaffolds made of PLGA have been used extensively for the controlled release of 
therapeutics from proteins to DNA to small interfering RNAs (siRNAs). A copolymer of 
lactic acid and glycolic acid, PLGA is FDA approved for clinical use, and offers the 
possibility of tunable mechanical and degradation properties by varying its inherent 
viscosity/molecular weight, molar ratio of its constituents, and the presence of end caps. 
The effects of growth factors are often highly dose dependent. TGF-β has shown 
inhibition of bone formation rate, and prolongation of mineralization lag time with high 
doses (Fujimoto, 1999). IGF-1 had a half-life of 240 minutes after intravenous injection 
in rats, while TGF-β1 had a half-life of 60-163 minutes (Zapf, 1986; Zioncheck, 1994). 
This necessitates large initial loading of the delivery device with growth factors to last 
during the entire duration of the treatment. Delivery of plasmids coding for the growth 
factors would be a more efficient form of therapy since the transfected cells themselves 
can control the synthesis and expression of the growth factors. Controlled delivery of 
plasmids coding for growth factors and their regulators can give cell-regulated, short-
term expression of therapeutic growth factors. But naked DNA without a carrier system is 
highly susceptible to endonuclease degradation (Kawabata, 1995). Plasmid DNA injected 
intravenously is rapidly cleared from plasma (Yoshida, 1996). Several viral and chemical 
carriers are available for intracellular delivery of plasmid DNA. Although transfection 
efficiencies with viral carriers are quite high, it has the disadvantage of generating 
immune response in the host and the possibility of integrating plasmid DNA with the host 
genome. Plasmid DNA has limited issues of toxicity and immunogenicity compared to 
viral vectors (Winn, 2000). Polyethylenimines are positively charged polymers due to the 
large number of amine groups, making them suitable to condense the negatively charged 
DNA and to facilitate their entry into cells (Bieber, 2002; Clamme 2003). PEI-DNA 
complexes are taken up by the cell, and the endosome is acidified, where the PEI acts as a 
proton sponge (Wightman). It is thought that the interaction of PEI amines with protons 
triggers osmotic swelling of the complex, causing the endosome to rupture and thus 
release the complexes into the cytoplasm (Wightman). Freeze-dried PEI:DNA complexes 
were mixed with granular PLGA and compression molded to create a DNA delivery 
device (Huang, 2003). Controlled delivery of PEI complexed DNA encoding BMP-4 
from PLGA scaffolds resulted in bone formation in a rat calvarial defect model (Huang, 
2005b).  
In an inductive approach to tissue engineering, a porous scaffold that provides 
space for tissue growth and differentiation is combined with local delivery of growth 
factors that can induce growth and differentiation of native precursor cells (Nof, 2002). 
This chapter of my dissertation presents our investigation of three types of PLGA for 
controlled release of naked and PEI-complexed DNA from porous PLGA scaffolds. 
Degradation profiles, mechanical properties and controlled release profiles of low 
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molecular weight hydrophilic PLGA, low molecular weight hydrophobic PLGA, and 
high molecular weight hydrophilic PLGA scaffolds were studied.  
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3.2 MATERIALS AND METHODS 
3.2.1 Plasmid 
Plasmids pEGFP-C1 and pDsRed2-C1 were obtained from Clontech. Figures 3.1 
and 3.2 show the physical maps of the plasmids used. The plasmids were propagated 
using the procedure described below in DH-5α sub-clonal efficiency cells, obtained from 
Invitrogen. DH-5α cells were thawed in ice for about 10 minutes. One µl of 500ng/µl 
plasmid was added to 100 µl of DH-5α cells in a tube. The tube was kept in ice for about 
30 minutes. The cells were then heat-shocked at 42ºC for 2 minutes. The cells were then 
put back in ice for 10 minutes. Nine hundred microlitres of SOC medium (Gibco) at 37ºC 
was added to the tube, and shaken at 37ºC, 225 rpm for 1 hour. The tube was centrifuged 
at 4000 rpm for about 20 seconds. 900 µl of supernatant was aspirated. The remaining 
medium and cells were resuspended. 80 µl of the transformed cells were plated on 100 
mm Petri dishes containing 40g/L LB Agar-Miller (Fisher Scientific) with 30 µg/ml 
Kanamycin (50 mg/ml, Sigma) added to it. The dishes were incubated upside down at 
37ºC overnight. They were then stored in the refrigerator until further use. 
 
 
 
Figure 3.1 Physical map of pDsRed2-C1 plasmid 
(http://www.clontech.com/images/pt/PT3603-5.pdf) 
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Figure 3.2 Physical map of pEGFP1-C1 plasmid 
(http://www.biocenter.helsinki.fi/bi/peranen/Kotisivunlinkit/Vectors/EGFP-C1.htm) 
 
3.2.1.1 Propogation and extraction of plasmid DNA 
To extract DNA, a colony was picked from the dish and transferred to 1 ml of 
Terrific broth (Fisher Biotech) in a culture tube, and shaken vigorously for 8 hours at 
37ºC. The Terrific broth had 0.06% v/v Kanamycin (50 mg/ml, Sigma) added to it. The 
starter culture was then added to 150 ml LB Broth in a 2L flask with 0.06% v/v 
Kanamycin and shaken overnight at 37ºC. The DNA from this culture was extracted 
using the GenElute HP Plasmid Maxiprep Kit (Sigma-Aldrich) following the 
manufacturer’s instructions. Absorbance of the extracted DNA at 260 nm and 280 nm 
was measured using a UV spectrophotometer (Hitachi U 2000), and only DNA with an 
absorbance ratio greater than 1.8 was used in further experiments. Concentration of the 
extracted DNA was determined by measuring the absorbance at 260 nm using UV 
spectrophotometer (Hitachi U 2000). 
 
3.2.2 Preparation of PEI:DNA complexes 
Branched PEI 50% w/v aqueous solution Mn ~1,200 was obtained from Sigma. It 
was diluted to 10 mM solution for use in this study. PEI:DNA complexes were prepared 
according to previously published protocol (Boussif 1995). PEI:DNA complexes with an 
N/P ratio of 5 or 14 were prepared for our experiments. Briefly, appropriate amount of 
10mM PEI was added drop wise to four milliliters of 500 µg/ml plasmid DNA with 1% 
sucrose. This PEI:DNA solution was quickly frozen to -80ºC and lyophilized for 3 days. 
Lyophilized PEI:DNA powder was resuspended in 700 µl of TE buffer. PEI was labeled 
with the amine-reactive probe Alexa488 (Molecular Probes/Invitrogen) using the 
manufacturer’s protocol. 
 
3.2.3 Preparation of PLGA microspheres 
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DNA-loaded microspheres were made using a W/O/W double emulsion method 
(Jain, 2000). In this study, 50:50 PLGA was obtained from Durect Corporation (Penham). 
50:50 PLGA with an inherent viscosity of 0.15-0.25 dL/g and acid end group is called 
low molecular weight hydrophilic, 50:50 PLGA with an inherent viscosity of 0.15-0.25 
dL/g and methyl ester end group is called low molecular weight hydrophobic PLGA, and 
50:50 PLGA with an inherent viscosity of 0.55-0.75 dL/g and acid end group is called 
high molecular weight hydrophilic PLGA. Six hundred and eighty microliters of DNA 
alone or PEI:DNA solution were added to 10% w/v PLGA  in methylene chloride. DNA 
solution was replaced with 680µl of TE buffer to create blank microspheres. This 
suspension was then vortexed for 30 seconds and added dropwise to rapidly spinning 1% 
polyvinyl alcohol (Sigma-Aldrich, MO) in deionized water to form the W/O/W emulsion. 
To create microspheres of high-molecular weight PLGA, a homogenizer was used to stir 
the suspension at 3500 rpm. Methylene chloride-DNA suspension was added drop wise 
to rapidly stirring PVA-water solution. The resulting suspension was homogenized using 
an Omni PDH (Omni International, GA) for 5 minutes. The emulsion was stirred 
overnight to evaporate methylene chloride, and the microspheres were collected using 
centrifugation. The collected microspheres were rinsed twice in deionized water and 
lyophilized for 48 hours before making discs. 
 
3.2.4 Porous PLGA discs 
To create porous PLGA discs for release experiments, 42 mg of PLGA 
microspheres were mixed by hand with 63 mg of 100-350 microns salt particles for 2 
minutes, and compressed at 1.5 tons for 2 minutes in a 6 mm die using a Carver press. 
One hundred and twenty milligrams of PLGA microspheres were mixed with 180 mg of 
salt particles for 2 minutes, and compressed at 6 tons for 2 minutes in a 13 mm die to 
create discs for in vitro and in vivo experiments. The ratio of salt to microspheres was 
increased to 70 wt% for hydrophobic discs in order to maintain the porosity of all discs at 
60%. 
The discs were then sintered in an oven for 48 hours at the Tg for PLGA. For low-
molecular weight PLGA, the sintering temperature was 42°C, while for high-molecular 
weight PLGA, the sintering temperature was 49°C. The sintered discs were then leached 
by stirring 6 discs/2L of deionized water overnight and dried in vacuum to create porous 
PLGA scaffolds. 
To create discs with freeze-dried DNA on top, 40μl of 500 μg/ml DNA solution 
containing 1% sucrose was added to the surface of previously prepared scaffolds and then 
lyophilized overnight. 
 
3.2.5 Mechanical testing of scaffolds 
Six millimeter diameter scaffolds were tested to failure using a Bose Electroforce 
3300. The rate of compression was set at 1 mm/minute (Leung, 2008), and scaffolds were 
compressed to 1.5mm. Load and displacement values were used to calculate stress and 
strain values. Stress-strain plots for different groups of scaffolds were generated using 
Excel, and ultimate stresses and compressive moduli were calculated. 
 
3.2.6 Mass loss of scaffolds 
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Scaffolds were immersed in 2 ml of PBS in 12 well plates, and incubated at 37°C 
with continuous shaking. PBS was replaced every 2 days. Scaffolds were collected at 
various time points and lyophilized for 48 hours before measuring their final weights. 
 
3.2.7 In vitro release and analysis 
In vitro release was performed in 2 ml PBS with 2 mM EDTA, pH 7.4, at 37°C 
with continuous shaking. The supernatant was collected and replaced every 24 hours. The 
amount of DNA in the supernatant was determined using a fluorometric Picogreen® 
(Molecular Probes/Invitrogen) assay according to the manufacturer’s instructions. For the 
Picogreen assay, the excitation/emission wavelengths were 480/520nm. Calf thymus 
DNA was used as a standard to calculate DNA mass from the fluorescence values. 
Alexa488 labeled PEI  release from microspheres was measured at an excitation/emission 
wavelengths of 488/520 nm. The pH of released supernatant was measured using a pH 
microelectrode. 
 
3.2.8 Statistical analysis 
Statistical analysis was performed using SAS 9.1 NC software. A p-value of 0.05 
was used for all statistical comparisons. The student’s t-test and ANOVA were used for 
comparing results between different groups. Tukey-Kramer multiple comparison test was 
used post-hoc. All figures show mean value +/- standard deviation for measured variable. 
All samples were in triplicate. Mixed models with repeated measures were used, to 
compare various release profiles.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
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3.3 RESULTS 
3.3.1 Mass loss of PLGA scaffolds 
 
3.3.1.1 Low molecular weight hydrophilic scaffolds 
Figure 3.3 shows the mass loss of low molecular weight hydrophilic scaffolds in 
PBS. Blank scaffolds had the highest slope, indicating the fastest mass loss, while 
PEI:DNA 5 encapsulated scaffolds had the lowest slope, indicating the slowest mass loss. 
Between days 5 and 15, PEI:DNA 5 encapsulated scaffolds lost their mass at an average 
rate of 4.6%/day. Naked DNA scaffolds had a mass loss rate of 5.3%/day during the same 
time period, while blank scaffolds lost mass at a rate of 6.2%/day. P-value for mixed-
model analysis of mass loss rates for different scaffold groups was greater than 0.05. 
Blank and DNA encapsulated scaffolds had loss their mass completely by day 30, while 
PEI:DNA encapsulated scaffolds still had 20% of their mass left at day 30. 
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Figure 3.3 Mass loss of low molecular weight hydrophilic scaffolds in PBS 
 
3.3.1.2 High molecular weight hydrophilic scaffolds 
Figure 3.4 shows the mass loss of high molecular weight hydrophilic scaffolds in 
PBS. These scaffolds degraded slower compared to the scaffolds made from low 
molecular weight hydrophilic PLGA. By day 20, high molecular weight PLGA scaffolds 
had lost only about 10% of their mass, whereas low molecular weight scaffolds had lost 
more than 60% mass by that time point. The initial phase of mass loss from high 
molecular weight PLGA scaffolds lasted until day 20, when the average mass loss was 
0.38%/day. P-value for mixed-model analysis of mass loss rates of blank scaffolds, naked 
DNA encapsulated scaffolds, and PEI:DNA encapsulated scaffolds was greater than 0.05. 
The second phase of mass loss was from day 20 to day 60. During this time, blank 
scaffolds lost mass at 2.05%/day, DNA encapsulated scaffolds last mass at 2.09%/day 
and PEI:DNA encapsulated scaffolds lost mass at 1.74%/day. P-value for mixed-model 
analysis of mass loss rates between days 20 and 60 for blank scaffolds, naked DNA 
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encapsulated scaffolds, and PEI:DNA encapsulated scaffolds was greater than 0.05. By 
day 60, blank scaffolds had lost 88% of their mass, while PEI:DNA encapsulated 
scaffolds had lost 77% of their mass. Mass loss for naked DNA encapsulated scaffolds 
was 93% at day 60. P-value for ANOVA of mass loss between different scaffold groups 
at day 60 was greater than 0.05. It appears that PEI:DNA encapsulated scaffolds had lost 
more mass at day 50 than at day 60. This is an experimental artifact, as one disc in the 
60-day batch degraded less compared to the other discs in the same batch. 
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Figure 3.4 Mass loss of high molecular weight hydrophilic scaffolds in PBS 
 
3.3.2 pH of release supernatant 
In order to understand the degradation kinetics of the scaffolds, the pH of the 
supernatant was measured. Figure 3.5 shows the pH of supernatant from low molecular 
weight hydrophilic scaffolds. pH started dropping from the starting value of 7.4, reaching 
4.7 for PEI:DNA 5 encapsulated scaffolds on day 8. It continued to rise after that time 
point until it reached 7.2 by day 30. pH of PEI:DNA encapsulated scaffolds were 
significantly higher compared to blank and DNA encapsulated scaffolds from day 4 until 
day 20 (p-value < 0.05), with the exception of day 8 when the difference was not 
statistically significant (p-value > 0.05). pH of the supernatant from blank and naked 
DNA encapsulated scaffolds showed values similar to each other throughout the 
experiment. They started around 7.4 and continued to decrease until day 16, reaching the 
lowest value of 3.5. Thereafter, they increased to the original value of 7.4 by day 30.  
Figure 3.6 shows the pH of supernatant collected from low molecular weight 
hydrophobic scaffolds. The pH of supernatant from blank scaffolds was around 7.8 until 
day 23, when it started dropped sharply to around 3.2 on day 46. It started rising back 
towards 7 on day 50. The pH of supernatant from blank scaffolds were significantly 
higher than naked DNA and PEI:DNA encapsulated scaffolds until day 34, and 
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significantly lower from day 38 until day 66 (p-value < 0.05). Naked and PEI:DNA 5 
encapsulated scaffolds started around pH 6.5, and steadily decreased to 4.8 by day 14, 
before rising gradually to reach 7 by day 55. There was no statistical difference in pH of 
naked and PEI:DNA encapsulated scaffolds (p-value  > 0.05), except at day 10, when 
PEI:DNA encapsulated scaffolds had significantly higher pH compared to naked DNA 
scaffolds (p-value < 0.05). Blank hydrophobic scaffolds reached their lowest pH on day 
46, compared to day 17 for blank hydrophilic scaffolds. Naked and PEI:DNA 
encapsulated hydrophobic scaffolds reached their lowest pH on day 14, compared to day 
16 for naked DNA encapsulated hydrophilic scaffold and day 8 for PEI:DNA 
encapsulated hydrophilic scaffolds. 
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Figure 3.5 pH of supernatant from degrading low molecular weight hydrophilic scaffolds 
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Figure 3.6 pH of supernatant from degrading low molecular weight hydrophobic 
scaffolds 
 
Figure 3.7 shows the pH from the high molecular weight hydrophilic scaffolds. 
Naked DNA and PEI:DNA 5 encapsulated scaffolds, as well as blank scaffolds showed 
similar values throughout the experiment. pH of the supernatant decreased from the 
starting value of 7.4, reaching the lowest value of 4.3 around day 38. After that pH started 
to rise, reaching a maximum of 6.8 by day 70. There were no statistical differences in the 
pH values (p-value > 0.05). All high molecular weight hydrophilic scaffolds reached their 
lowest pH around days 40-45, compared to days 8-16 for low molecular weight 
hydrophilic scaffolds. 
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Figure 3.7 pH of supernatant from degrading high molecular weight hydrophilic scaffolds 
 
3.3.3 Mechanical testing of PLGA scaffolds 
Figures 3.8 is a representative stress-strain plot from the mechanical testing of 
low molecular weight PLGA scaffold. A brief toe region can be seen at the beginning of 
the plot. After that, stress increased linearly with strain, until the sample failed at around 
1.45 MPa. Both the high molecular weight and low molecular weight PLGA scaffolds 
showed linear stress-strain relationships, but they differed in their ultimate compressive 
strengths as well as compressive moduli, as evident in Figures 3.9 and 3.10. 
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Figure 3.7 Representative stress-strain curve for low molecular weight hydrophilic 
scaffold 
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3.3.3.1 Effect of molecular weight on mechanical properties 
Figures 3.9 and 3.10 show the effect of molecular weight of PLGA on 
compressive moduli and ultimate strength of scaffolds, respectively. Blank scaffolds 
made from low molecular weight PLGA had an average compressive modulus of 29.2 
MPa, while blank scaffolds made from high molecular weight PLGA had an average 
compressive modulus of 78.46 MPa. The difference in compressive modulus between 
these two types of scaffolds was statistically significant, with a p-value < 0.05. PEI:DNA 
encapsulated scaffolds made from low molecular weight PLGA had an average 
compressive modulus of 25.51 MPa, while the average compressive modulus for high 
molecular weight PEI:DNA scaffolds was 81.13 MPa. The difference in compressive 
modulus between high and low molecular weight PEI:DNA 14 scaffolds was also 
statistically significant, with a p-value < 0.05. 
Low molecular weight blank scaffolds had an average ultimate strength of 1.86  
MPa, while their high molecular weight counterparts had a statistically significantly 
higher ultimate strength of 5.94 MPa (p-value < 0.05). Low molecular weight PEI:DNA 
14 scaffolds had an average ultimate strength of 1 MPa, while their high molecular 
weight counterparts had a statistically significantly higher average ultimate strength of 
7.2 MPa (p-value < 0.05). 
 
3.3.3.2 Effect of PEI:DNA encapsulation on mechanical properties 
Figure 3.9 Compressive moduli of PLGA scaffolds 
 
Figures 3.9 and 3.10 also show the effect of PEI on the mechanical properties of 
PEI:DNA encapsulated scaffolds compared to blank scaffolds. There was no significant 
difference between the compressive modulus of blank scaffolds and PEI:DNA 
encapsulated scaffolds for both low molecular or high molecular PLGA (p-value > 0.05). 
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This was not the case for ultimate strength. Ultimate strength for low molecular weight 
blank scaffolds was 1.86 MPa, while low molecular weight PEI:DNA encapsulated 
scaffolds had a statistically significantly lower ultimate strength of 1 MPa (p-value < 
0.05). High molecular weight blank scaffolds had an average ultimate strength of 5.94 
MPa, while high molecular weight PEI:DNA scaffolds had a higher average ultimate 
strength of 7.21 MPa. This difference was not statistically significant (p-value > 0.05). 
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Figure 3.10 Ultimate strength of PLGA scaffolds. * denotes p-value < 0.05 between 
LMW blank and LMW PEI:DNA 14 
 
3.3.4 DNA release from PLGA scaffolds 
 
3.3.4.1 Low molecular weight hydrophilic PLGA 
 
3.3.4.1.1 DNA release from microspheres alone 
DNA release from low molecular weight hydrophilic PLGA microspheres that 
had naked DNA encapsulated is shown in Figure 3.11. DNA was detected in the 
supernatant from the first day of release. A peak release of 2.3 µg/ml was seen on the first 
day, followed by rapid decrease until day 18.  
* 
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Figure 3.11 Naked DNA release profile for low molecular weight hydrophilic PLGA 
microspheres 
3.3.4.1.2 DNA release from scaffolds 
Figure 3.12 shows the release of encapsulated naked and PEI-complexed DNA 
from low molecular weight hydrophilic PLGA scaffolds. Naked and complexed DNA 
were detected in the supernatant from the first days of release. Both releases had biphasic 
profiles, with the first phase due to the release of surface bound naked and PEI:DNA 
polyplex, and the second phase from the swelling of scaffolds and release of naked and 
PEI:DNA polyplex from the interior of the scaffolds. Naked DNA release showed a peak 
around days 7-10 with 0.25 to 0.27 µg/ml of supernatant. The release of naked DNA was 
over by day 16. PEI:DNA 5 complexes showed a slightly different release profile 
compared to naked DNA particles. The initial phase of release lasted longer, ending by 
day 7, compared to day 4 for naked DNA particles. The concentration of PEI:DNA 
particles was also higher compared to naked DNA until day 5. The second peak of 
PEI:DNA release occurred on day 10, compared to days 7-10 for naked DNA. The 
release of PEI:DNA particles was complete by day 20. 
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Figure 3.12 Naked and PEI complexed DNA release from low molecular weight 
hydrophilic PLGA scaffolds 
 
The fractional cumulative release of naked and PEI complexed DNA particles 
from low molecular weight hydrophilic scaffolds can be seen in Figure 3.13. PEI:DNA 
encapsulated scaffolds released majority of their contents earlier than naked DNA 
encapsulated scaffolds although they had their second phase release later than naked 
DNA encapsulated scaffolds. This is evident by comparing the fraction of DNA released 
at day 6 for both types of scaffolds. By day 6, PEI:DNA encapsulated scaffolds had 
released 72% of their total content, while DNA encapsulated scaffolds had released only 
31% of their total content. PEI:DNA encapsulated scaffolds, however, continued to 
release complexes for a longer duration. Naked DNA encapsulated scaffolds had an 
average release rate of 2.7%/day during the first phase, and 9.6%/day during the second 
phase of release, compared to 12.5%/day during the first phase, and 4.3%/day during the 
second phase for PEI:DNA encapsulated scaffolds. Mixed model analysis of the release 
rates during the first phase gave a p-value less than 0.05, while the p-value for the release 
rates during the second phase was greater than 0.05. PEI:DNA encapsulated scaffolds 
completed their release by day 20, compared to naked DNA encapsulated scaffolds that 
completed their release by day 16. 
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Figure 3.13 Cumulative fractional release of PEI:DNA 5 and DNA from low molecular 
weight hydrophilic PLGA scaffolds 
 
 
3.3.4.1.3 Effect of additional freeze-dried layer on surface 
An additional layer of naked DNA was freeze-dried onto the surface of scaffolds 
to increase the initial amount of DNA released. Figure 3.14 shows the combined release 
of freeze-dried and encapsulated DNA from PLGA scaffolds, while Figure 3.15 shows 
the release of encapsulated DNA alone from scaffolds. Superimposed release profiles 
from Figures 3.14 and 3.15 can be seen in Figure 3.16. The initial burst release of freeze-
dried DNA was over by one week, after which the release profile of both types of 
scaffolds looked comparable. The initial amount of DNA released from scaffolds that had 
a freeze-dried layer of DNA was 87 fold higher than that from scaffolds with 
encapsulated DNA alone (2.6µg/ml as opposed to 0.03µg/ml). This difference was 
statistically significant with a p-value less than 0.05. 
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Figure 3.14 Release of freeze-dried and encapsulated naked DNA from low molecular 
weight hydrophilic PLGA scaffolds 
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Figure 3.15 Release of encapsulated naked DNA from low molecular weight hydrophilic 
PLGA scaffolds 
 
The peak release on day 16 was statistically significantly higher than the release values 
until day 12 (p-value < 0.05). 
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Figure 3.16 Superimposed release profiles of encapsulated and freeze-dried naked DNA 
from low molecular weight hydrophilic PLGA scaffolds 
 
3.3.4.1.4 Release of fluorescently labeled PEI 
Complexation of DNA with PEI resulted in reduced detectablity of DNA using 
normal DNA assays. Therefore, PEI used for making PEI:DNA complexes was labeled 
using Alexa-480 to track its release from PLGA scaffolds. The results can be seen in 
Figure 3.17. PEI was detected in the supernatant from the first day of release. The release 
profile showed a typical biphasic pattern. The first phase of release for PEI:DNA 5 
encapsulated scaffolds was over by day 7, while for scaffolds with PEI:DNA 14 
complexes, the first phase continued until day 15. The second peak in release for 
PEI:DNA 5 encapsulated scaffolds lasted from day 27 to day 34, while for PEI:DNA 14 
encapsulated scaffolds the second peak was from day 27 to 39. PEI:DNA 14 encapsulated 
scaffolds showed higher fluorescence values at all time points compared to scaffolds with 
PEI:DNA 5 complexes. 
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Figure 3.17 Release profile of fluorescently labeled PEI released from low molecular 
weight hydrophilic PLGA scaffolds 
 
In addition to tracking fluorescently labeled PEI, DNA was also assayed from the 
same set of scaffolds. This afforded us the ability to simultaneously and independently 
track the release of both PEI and DNA. DNA release profile from the scaffolds can be 
seen in Figure 3.18. The first phase of PEI:DNA release started on day 1 and ended by 
day 5, whereas the second phase of release started on day 25 and ended by day 34. Figure 
3.18 shows the excellent correlation between PEI and DNA release profiles. Variability 
between samples around day 30 was high as samples started disintegrating into smaller 
pieces. 
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Figure 3.18 Superimposed release profiles of labeled PEI  and DNA from low molecular 
weight hydrophilic PLGA scaffolds 
 
3.3.4.2 Low molecular weight hydrophobic PLGA 
Naked and PEI complexed DNA was encapsulated within methyl-terminated low 
molecular weight PLGA to study the effect of hydrophobicity on release behavior. Figure 
3.19 shows the release profile of naked DNA from hydrophobic PLGA scaffolds. The 
release started on day 1 after incubation and continued until day 64. The first phase of 
release was over by day 3, after which the second phase of release started. The second 
phase of release peaked on day 9 and continued to decrease until day 35, after which 
there was almost constant release. 
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Figure 3.19 Release profile of naked DNA from low molecular weight 
hydrophobic PLGA scaffolds 
 
Complexing of DNA with PEI resulted in a release profile shown in Figure 3.20. 
The first phase consisted of a sustained release of 0.35 µg/ml PEI:DNA complexes until 
day 10, after which the second phase of release started. The second phase of release 
peaked around day 15 and continued to decrease afterwards.  PEI:DNA complexes were 
detected in the supernatant until day 65. 
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Figure 3.20 Release profile of PEI:DNA 5 complexes from low molecular weight 
hydrophobic PLGA scaffolds 
 
Figure 3.21 shows the fractional cumulative release of naked and PEI:DNA 5 
complexes from low molecular weight hydrophobic PLGA scaffolds. Scaffolds with 
encapsulated naked DNA had a faster release than scaffolds with encapsulated PEI:DNA 
5 complexes. By day 30, naked DNA encapsulated scaffolds had released 68% of their 
content, while PEI:DNA encapsulated scaffolds had released only 51% of their contents. 
Both sets of scaffolds completed release by day 70. Naked DNA encapsulated scaffolds 
had an average release rate of 1.2 %/day during the second phase of their release, 
compared to 0.91%/day for PEI:DNA encapsulated scaffolds. Mixed model analysis of 
this difference in release rates gave a p-value less than 0.05. 
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Figure 3.21 Fractional cumulative release of naked and PEI:DNA complexes from 
low molecular weight hydrophobic PLGA scaffolds 
 
3.3.4.3 High molecular weight hydrophilic PLGA 
Naked and PEI:DNA complexes were encapsulated in higher molecular weight 
hydrophilic PLGA scaffolds and their release characterized in order to study the effect of 
PLGA molecular weight on release profile. Figure 3.22 shows the release profile of 
naked DNA from high molecular weight (HMW) hydrophilic PLGA scaffolds. The first 
phase of release started on day 1 and was over by day 10. The second phase of release 
started on day 26 and peaked on day 36. The second phase of release ended by day 50. 
Complexation of DNA with PEI resulted in a later second phase of release as seen in 
Figure 3.23. The first phase of PEI:DNA release started on day 1 and continued until day 
26. The second phase of release started on day 28, peaked around day 50, and continued 
until day 70. Variability between samples was high during peak release, as samples 
started disintegrating into smaller fragments. 
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Figure 3.22 Release profile of naked DNA from high molecular weight hydrophilic 
PLGA scaffolds 
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Figure 3.23 Release profile of PEI:DNA 5 complexes from high molecular weight 
hydrophilic PLGA scaffolds 
 
Fractional cumulative release of naked and PEI complexed DNA from high 
molecular weight hydrophilic PLGA can be seen in Figure 3.24. Both kinds of scaffolds 
had similar release rates during the first phase of release. PEI:DNA encapsulated DNA 
had a slower release during the second phase, as evidenced by a lower slope in Figure 
3.24. During the second phase of release DNA encapsulated scaffolds had an average 
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release rate of 7.1%/day compared to 3.05%/day for PEI:DNA encapsulated scaffolds. 
Mixed model analysis of this difference in release rates gave a p-value less than 0.05. 
 
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75
Days
C
um
ul
at
iv
e 
fra
ct
io
n
Naked DNA
PEI:DNA 5
 
Figure 3.24 Fractional cumulative release of naked and PEI:DNA complexes from 
high molecular weight hydrophilic PLGA scaffolds 
 
When comparing naked DNA and PEI:DNA encapsulated scaffolds, PEI:DNA 
encapsulated scaffolds consistently showed a delayed peak release irrespective of 
hydrophilicity or molecular weight of PLGA (Table 3.1). Molecular weight of the 
polymer used to make microspheres had an effect on the release profile of naked and 
PEI:DNA complexes. Table 1 shows that scaffolds made from higher molecular weight 
polymer had a later peak release of both naked and PEI:DNA complexes compared to 
lower molecular weight polymer. Hydrophilicity of the polymer also had an effect on 
release profile. Scaffolds made from hydrophilic polymer had a later peak release of both 
naked and PEI:DNA complexes compared to scaffolds made from hydrophobic polymer 
of similar molecular weight. Figures 3.25 and 3.26 illustrate how the release profiles of 
naked and PEI:DNA 5 complexes were altered depending on the hydrophilicity and 
molecular weight of PLGA. 
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Table 3.1 Day of peak release for different molecular weight and hydrophilicity of 
PLGA. 
Day of peak release 
 LMW Hydrophilic LMW Hydrophobic HMW Hydrophilic 
Naked DNA Day 16 Day 8 Day 36 
PEI:DNA 5 Day 30 Day 15 Day 50 
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Figure 3.25 Fractional cumulative release of naked DNA from PLGA scaffolds 
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Figure 3.26 Fractional cumulative release of PEI:DNA 5 from PLGA scaffolds 
 
 42 
3.4 DISCUSSION 
 
3.4.1 Effect of PEI on mass loss 
 
3.4.1.1 Low molecular weight PLGA scaffolds 
We observed that PEI was effecting the rate of degradation of PEI:DNA 
encapsulated scaffolds. PEI:DNA encapsulated scaffolds degraded at a lower rate 
compared to naked DNA encapsulated scaffolds and blank scaffolds. At the end of 30 
days of degradation experiment, PEI:DNA encapsulated scaffolds had lost only 80% of 
their mass, while naked DNA encapsulated scaffolds and blank scaffolds had degraded 
completely. It is possible that the branched PEI used in our study, with its structure and 
positive charge, was interacting with the negatively charged PLGA polymer molecules 
and slowing their degradation. The interaction between PEI and PLGA is in fact used for 
attaching PEI to PLGA microspheres using a technique called layer-by-layer deposition. 
PEI deposited on PLGA microspheres was used for coating TGF-β3 loaded nanoparticles 
for growth factor delivery (Park, 2008).  
Comparison of the mass loss profile with naked and PEI:DNA 5 release from low 
molecular weight scaffolds shows that there is good correlation between the time points 
of peak degradation of scaffolds and peak DNA release. The second phase of naked DNA 
release was seen around days 5 to 15, while peak degradation occurred around days 5-20. 
The second phase of PEI:DNA 5 release from the scaffolds occurred between days 5-25, 
while peak degradation was observed around days 7 to 14. We observed a low 
concentration sustained release after the second phase release in most release 
experiments, probably from the release of any adsorbed DNA or PEI:DNA particles from 
the walls of the tubes in which the scaffolds were degrading. 
 
3.4.1.2 High molecular weight PLGA scaffolds 
PEI did not significantly effect the degradation rate of high molecular weight 
PLGA scaffolds, in contrast to the results from low molecular weight PLGA scaffolds. 
Although the mass loss rate for PEI:DNA encapsulated scaffolds was lower than that of 
blank and naked DNA encapsulated scaffolds, these differences were not statistically 
significant. It is possible that the electrostatic interaction between PEI and high molecular 
weight PLGA is not as strong as that with low molecular weight PLGA, as the longer 
chain lengths of high molecular weight PLGA means less negative charge per unit mass 
of polymer for interacting with positively charged PEI. It has been shown that higher 
molecular weight hydrophilic PLGA has a lower acid number, and less negative charge 
compared to lower molecular weight hydrophilic PLGA, leading to less interaction with 
positively charged BMP-2 molecules (Schrier, 1999). 
There was good correlation between degradation and release profiles for both 
naked DNA and PEI:DNA encapsulated scaffolds. Naked DNA encapsulated scaffolds 
had the highest mass loss rate between 20 and 50 days. The peak naked DNA release was 
also observed between days 30 and 50. PEI:DNA encapsulated scaffolds had the highest 
mass loss rates between days 30 and 50, while PEI:DNA release from the scaffolds 
started increasing from day 30, reaching its peak around day 50.  
 
3.4.2 pH of release supernatant 
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We set out to gain insight into the differences in degradation behavior of various 
PLGA scaffolds by measuring the pH of release supernatant. Our hypothesis was that a 
drop in pH would indicate increased degradation of scaffolds, and would allow us 
indirectly to observe the degradation profile of various kinds of PLGA scaffolds. 
However, this hypothesis was only partly proven to be true. In the case of hydrophobic 
scaffolds, there was significant differences in the pH profile between naked DNA and 
PEI:DNA 5 encapsulated scaffolds and blank scaffolds. Blank scaffolds showed a drop in 
pH almost 30 days later than naked DNA and PEI:DNA 5 encapsulated scaffolds. This 
was in contradiction to what we saw from the release experiments, which showed peak 
naked DNA release from hydrophobic scaffolds between 5 and 15 days, and peak 
PEI:DNA 5 release between 10 and 25 days. Mass loss studies using hydrophobic 
scaffolds in the future might help us explain the apparent difference in pH and release 
profiles. 
For low molecular weight hydrophilic scaffolds, there was some agreement 
between the pH profile of supernatant, and release profile. Drop in pH occurred first for 
blank scaffolds and naked DNA scaffolds around day 5, while the first significant drop in 
pH for PEI:DNA 5 encapsulated scaffolds occurred around day 8. This correlated with 
the earlier second phase of release seen for naked DNA encapsulated scaffolds compared 
to PEI:DNA 5 encapsulated scaffolds. However, pH of release supernatant from naked 
DNA and blank scaffolds continued to drop until day 17, while pH from PEI:DNA 5 
scaffold supernatant steadily recovered to baseline value after day 10. For scaffolds made 
from high molecular weight hydrophilic PLGA, pH of supernatant from blank scaffolds 
and naked DNA encapsulated scaffolds reached their lowest value on day 37, while the 
lowest point was reached on day 47 for PEI:DNA 5 encapsulated scaffolds. This 
correlated well with the second phase of release from these scaffolds, which peaked 
around day 35 and day 50, respectively.  
Although pH of release supernatant provided an approximate indication of 
degradation of scaffolds, it proved to be an unreliable and imprecise indicator of 
degradation profile of PLGA scaffolds. 
 
3.4.3 Mechanical properties of scaffolds 
A biomaterial that is designed to replace or augment a tissue should ideally have 
mechanical properties that match that of the host tissue. This becomes an even greater 
challenge in the case of devices that are intended to replace complex tissues like 
cartilage, since the mechanical properties of cartilage depends on the zone within it. 
Compressive modulus of cartilage is provided in large part by the proteoglycans within 
the extracellular matrix of cartilage (Schinagl, 1997). Compressive modulus increases 
with increasing density of fixed charge (Grodzinsky, 1990), which in turn increases with 
depth into the cartilage (Maroudas, 1979). Compressive modulus of articular cartilage 
increased significantly with depth from 0.079 MPa in the superficial layer to 2.1 MPa in 
the deepest later (Schinagl, 1997). Similar depth dependent variation in mechanical 
properties was seen in growth plate cartilage also. Growth plates are designed for rapid 
interstitial growth, but should also withstand large mechanical forces (Radhakrishnan, 
2004). Young’s modulus for rabbit growth plate cartilage varied from 0.57 MPa in the 
reserve zone to 1.44 MPa in the mineralizing zone (Radhakrishnan, 2004). 
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Compressive modulus for our scaffolds varied from 25.51 MPa for low molecular 
weight PLGA, to 81.13 MPa for high molecular weight PLGA. Porous 50:50 PLGA 
scaffolds with a porosity of 85% had a compressive modulus of 1.7 MPa when loaded at 
1 mm/minute (Leung, 2008). Higher porosity of these scaffolds compared to our samples 
might be the reason for the much lower compressive modulus. Although our compressive 
modulus values are an order of magnitude greater than the modulus for growth plate 
cartilage, we expect that these values will decrease significantly when the scaffolds 
become wet after insertion into the implant site. 
 
3.4.4 DNA release from PLGA microspheres 
PLGA microspheres have been used previously for delivery of plasmid DNA in 
vitro and in vivo. In addition to providing the ability to control the release of plasmid 
DNA, encapsulation protects the DNA from enzymatic degradation and enhances the 
retention its supercoiled structure (Gebrekidan, 2000). A single phase release profile 
similar to ours was seen with most of the release over in 2 weeks (Gebrekidan, 2000). 
PLGA microspheres with encapsulated DNA can be useful in applications such as DNA 
vaccines, but regenerating a complex tissue like growth plate would benefit from a 
biodegradable porous scaffold that can be inserted into a defect. 
 
3.4.5 Release from PLGA scaffolds 
PLGA scaffolds have been used for controlled release of both adsorbed and 
encapsulated plasmid DNA. Controlled release from a scaffold can provide sustained 
release of plasmid DNA, which is not possible with bolus injections. Porous matrices 
made of PLGA provided sustained release of encapsulated naked DNA for 10 to 30 days 
(Shea, 1999). Sustained release of naked plasmid DNA for 21 days was achieved from 
PLGA scaffolds manufactured using a thermally-induced phase-separation method 
(Chun, 2004).  
Our scaffolds showed peak naked DNA release around days 7-10 with 0.25 to 
0.27 µg/ml of supernatant. Release of naked DNA was over by day 16. Release profile of 
PEI:DNA 5 particles from our scaffolds differed in both time and concentration 
compared to the release profile of naked DNA. The initial phase of release lasted longer, 
ending by day 7, compared to day 4 for naked DNA particles. The concentration of 
PEI:DNA particles was also higher compared to naked DNA until day 5. The second 
peak of PEI:DNA release occurred on day 10, compared to days 7-10 for naked DNA. 
The release of PEI:DNA particles were complete by day 20. The slight delay in peak 
release as well as longer release duration might be from the interaction between PEI and 
PLGA. Electrostatic interaction between positively charged histones and negatively 
charged release substrates has been reported previously (Lee, 2006b). Less than 20% of 
PEI:DNA particles were released from PLGA scaffolds by 15 days, compared to 80% of 
naked DNA, suggesting interaction between PLGA and PEI (Huang, 2003). It was also 
proposed that excess PEI from the making of PEI:DNA particles might be interacting 
electrostatically with PLGA (Huang 2003). At N/P ratio of 6, approximately 86% of the 
PEI used to make PEI:DNA complexes remain in their free form (Clamme, 2003b). 
Surface adsorption of PEI:DNA particles on PLGA scaffolds resulted in an N/P ratio-
dependent release of these particles (Jang, 2006). At the end of 4 days of release, 90% of 
adsorbed PEI:DNA 6 particles were released, while only 40% of PEI:DNA 18 particles 
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were released (Jang, 2006). Electrostatic and physical interaction between the positively 
charged PEI and PEI:DNA particles, and negatively charged PLGA molecules, can slow 
down the dissolution of PLGA scaffolds as well as release of PEI:DNA particles from 
PLGA scaffolds. 
We consistently saw that the concentration of released PEI:DNA from scaffolds 
was higher than the concentration of naked DNA, even though both kinds of scaffolds 
were manufactured identically. Some of this effect can be explained by the technique 
employed to measure concentration of released DNA in the supernatant. Concentration of 
DNA from our release experiments was measured using the Picogreen® assay. Picogreen 
dye binds to double stranded DNA and fluoresces, allowing us to determine the 
concentration of DNA using a standard curve. The very property of PEI which enables us 
to condense DNA into toroidal particles, also limits our ability to detect DNA once it has 
been condensed. Picogreen® reagent binds less efficiently to PEI:DNA particles as the 
ratio of PEI to DNA increases, until it becomes impossible to detect DNA at high 
PEI:DNA ratios. This is the reason PEI:DNA ratio was kept at 5 in all our release 
experiments, so that we could use Picogreen® assay to detect DNA in the release 
supernatant. We calculated PEI:DNA 5 concentrations using PEI:DNA 5 calibration 
curves, but even a small amount of free DNA in the supernatant could have artificially 
increased the apparent concentration of PEI:DNA 5. Most researchers report PEI:DNA 
release as fractional cumulative release, which circumvents this problem. We are 
reporting both instantaneous and cumulative release of PEI:DNA 5 from our scaffolds, 
with a caveat that the instantaneous release profile should be used more as an indication 
of time profile rather than the absolute values of DNA concentration. 
Addition of a freeze-dried layer of naked DNA on DNA encapsulated scaffolds 
can provide an initial burst release to “jump-start” the transfection of cells attaching to 
the scaffolds in vitro and in vivo. Our results show that this additional layer of DNA was 
bound only to the surface of the scaffolds. Surface adsorption of PEI:DNA 6 particles 
resulted in 90% of the particles being released within 4 days (Jang, 2006). We saw a 
similar quick release of freeze-dried DNA, that was over in 9 days, after which these 
scaffolds behaved similarly to DNA encapsulated scaffolds. 
Fluorescent labeling of PEI enabled us to track its release simultaneously with 
DNA, and showed excellent correlation between these two releases. This also confirmed 
that the results from using Picogreen® to track PEI:DNA 5 release were not artifacts, and 
that Picogreen® was effective in detecting PEI:DNA 5 in supernatant. 
 
3.4.5.1 Effect of hydrophobic PLGA on release 
Naked and PEI complexed DNA was encapsulated within methyl-terminated 
(hydrophobic) low molecular weight PLGA to study the effect of hydrophobicity on 
release behavior. Scaffolds with encapsulated naked DNA had a faster release than 
scaffolds with encapsulated PEI:DNA 5 complexes, as seen with low molecular weight 
hydrophilic PLGA scaffolds. Eighty percentage of encapsulated naked DNA was released 
by day 42, while only 60% of encapsulated PEI:DNA 5 was released by the same time. 
When comparing the release of naked and PEI-complexed DNA from hydrophobic 
scaffolds with their hydrophilic scaffolds, we saw that peak releases from hydrophobic 
scaffolds occurred 1 to 2 weeks earlier than from the hydrophilic scaffolds. Peak release 
of naked DNA from hydrophilic scaffolds occurred around day 16 while it occurred 
 46 
around day 8 from hydrophobic scaffolds. Similarly, peak PEI:DNA 5 release from 
hydrophilic scaffolds occurred around day 30, while it occurred around day 15 for 
hydrophobic scaffolds. This is counter-intuitive since we expected the hydrophobic 
scaffolds to degrade slower than the hydrophilic scaffolds. Similar results were seen 
when hydrophobic and hydrophilic PLGA microspheres were used for the released of 
encapsulated TGF-β. Microspheres made of hydrophobic PLGA released 100% of 
encapsulated TGF-β within the first four days, while microspheres made from 
hydrophilic PLGA did not show any significant release until after the first four days 
(Jaklenec, 2008). Hydrophilic PLGA, with its acid end groups, is thought to enhance 
protein-polymer interactions, and better internalize proteins within polymer microspheres 
(Jaklenec, 2008). Similar DNA-PLGA and PEI:DNA-PLGA interactions might be 
enhanced with acid-end groups in hydrophilic PLGA, leading to a delayed release profile 
compared to hydrophobic PLGA. We also observed a softening and collapse of the pore 
structure of hydrophobic PLGA scaffolds during an ethanol sterilization process. Hence, 
we discontinued the use of hydrophobic PLGA scaffolds in further studies. 
 
3.4.5.2 Effect of molecular weight of PLGA on release 
We encapsulated naked and PEI:DNA complexes in higher molecular weight 
hydrophilic PLGA scaffolds, and their release was characterized in order to study the 
effect of PLGA molecular weight on release profile. Complexation of DNA with PEI 
resulted in a later second phase of release compared to naked DNA, as seen in both low 
molecular weight hydrophilic scaffolds and low molecular weight hydrophobic scaffolds. 
Compared to scaffolds made from low molecular weight hydrophilic PLGA, peak release 
of both naked and PE:DNA complexes occurred at a later time for scaffolds made from 
high molecular weight PLGA. This was expected as polymer chains of higher molecular 
weight PLGA will take longer to be hydrolyzed into oligomers that are soluble in water. 
Porous scaffolds made from PLGA with an inherent viscosity of 0.6-0.8 dl/g (low 
molecular weight) released about 90% of their encapsulated naked DNA by 21 days, 
compared to 50% for scaffolds made from PLGA with an inherent viscosity of 0.16-0.24 
dl/g (high molecular weight) (Jang, 2003). Microspheres made from PLGA with a 
molecular weight of 10,000 released 95% of their encapsulated poly(L-Lysine)-DNA 
complexes by 40 days, compared to 50% of encapsulated PLL-DNA complexes from 
microspheres made of PLGA with a  molecular weight of 31,000 (Capan, 1999). We 
observed similar effects with 20% of naked and PEI:DNA complexes being released from 
high molecular weight PLGA scaffolds within 30 days, compared to 100% of 
encapsulated naked and PEI:DNA 5 complexes from low molecular weight PLGA 
scaffolds. 
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3.5 CONCLUSIONS 
Controlled release of naked and PEI:DNA complexes was achieved from porous 
PLGA scaffolds. PEI effected the release of complexes from PLGA scaffolds, as 
PEI:DNA complexes were released at a lower rate compared to naked DNA from low 
molecular weight and high molecular weight PLGA scaffolds, as well as hydrophilic and 
hydrophobic PLGA scaffolds. Hydrophilicity and molecular weight of PLGA had effects 
on the release profiles of both naked DNA and PEI DNA complexes from the scaffolds, 
as evidenced by later peak naked DNA and PEI:DNA release with increasing 
hydrophilicity and molecular weight. Compressive modulus and ultimate strength for 
high molecular weight PLGA scaffolds were significantly higher than low molecular 
weight PLGA scaffolds. Although pH of release supernatant provided an approximate 
indication of degradation of scaffolds, it proved to be an unreliable and imprecise 
indicator of degradation profile of PLGA scaffolds. Porous scaffolds made of PLGA with 
the right hydrophobicity and molecular weight will allow us to tailor degradation profiles 
and mechanical properties of these scaffolds for controlled delivery of naked and 
condensed plasmid DNA in tissue engineering applications.  
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4. IN VITRO CHONDROGENESIS USING IGF-I AND POROUS PLGA 
SCAFFOLDS 
 
4.1 INTRODUCTION 
Cartilage is a major connective tissue in the body, serving as structural support, 
growth plates, and articulating surfaces at the ends of long bones. Because of its limited 
regeneration potential, there is tremendous interest in developing modalities to regenerate 
cartilage lost due to aging, disease and trauma. Using pulripotent cells in combination 
with a biodegradable scaffold is one approach that is being pursued towards regenerating 
cartilage, particularly articular cartilage. The biodegradable scaffolds are designed to give 
structural and mechanical support to the newly synthesized tissue as it develops, while 
the chondrogenic cells are intended to populate the scaffold and generate the 
cartilaginous tissue. A growth factor such as TGF-β or IGF-I, is often added to the recipe, 
being synthesized by the cells themselves or released by the matrix, to stimulate the cells 
to become chondrogenic (Choi, 2007; Capito, 2007). 
 Several cell types have been investigated for growing cartilaginous tissue on 
biodegradable scaffolds. Poly(glycolic acid) based scaffolds as well as agarose based 
hydrogels have been used to induce chondrogenesis from mesenchymal stem cells 
(Kafienah, 2007; Chen, 2003). Mesenchymal stem cells are multipotential cells that can 
differentiate into cells of mesenchymal lineage, such as chondrocytes, osteocytes and 
adipocytes, under appropriate culture conditions (Pittenger, 1999). Mesenchymal cells 
infected with AdIGF-I and suspended in fibrin glue have been used for successful repair 
of articular cartilage (Gelse, 2003). Bone marrow stromal cells (BMCs) have been shown 
to be particularly useful in tissue engineering because of their excellent proliferation and 
matrix production (Eijk, 2004). BMCs have been cultured in combination with TGF-β1 
on PLGA scaffolds, which resulted in significant cell proliferation and chondrocytic 
differentiation (Jenner, 2007). They have also been seeded on silk scaffolds and grown in 
a rotating bioreactor with dexamethasone, TGF-β and insulin ,resulting in significantly 
higher DNA and GAG content compared to controls that did not receive the growth 
factors (Marolt, 2006). Previous studies have shown that ex vivo transfer of IGF-I DNA 
into chondrocytes can enhance chondrogenesis in vitro and in vivo (Madry, 2002; Madry, 
2005). Significant chondrogenesis was reported with IGF-I plasmid-transfected 
chondrocytes cultured on collagen-GAG scaffolds (Xu, 2008).  
Using a porous scaffold that can release the plasmid that codes for a chondrogenic 
growth factor eliminates the need to collect and expand progenitor cells, with its 
associated cost and morbidity, and meets the challenge of sustained local delivery of 
therapeutic doses of growth factors. This chapter of my dissertation presents our in vitro 
studies on chondrogenesis using mesenchymal multipotent D1 cells, bone marrow cells 
and articular chondrocytes on PLGA and PLGA-fibrin scaffolds, with the addition of 
exogenous rhIGF-I. Finally it presents our development of IGF-I plasmid releasing 
scaffolds, to be used for chondrogenesis by culturing bone marrow cells without the need 
for exogenous IGF-I addition. Chapter 5 presents our use of such IGF-I plasmid releasing 
scaffolds to regenerate growth plate cartilage in an animal model of growth plate injury. 
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4.2 MATERIALS AND METHODS 
4.2.1 Plasmids 
Recombinant hIGF-I plasmid SC119792 was obtained from OriGene. Figure 4.1 
shows the physical map of the plasmid. DH-5α cells were transformed using plasmids as 
explained in section 3.2.1. 
 
Figure 4.1 Physical map of rhIGF-I plasmid 
(http://www.origene.com/assets/Documents/catalog_manual/AppGuideTrueclone10ug.pdf) 
 
4.2.2 Propagation and extraction of plasmid DNA 
Propagation and extraction of plasmid DNA was done as explained in section 
3.2.1.1. 
 
4.2.3 Preparation of PEI:DNA complexes 
PEI:DNA complexes were prepared as explained in section 3.2.2. 
 
4.2.4 Preparation of PLGA microspheres 
PLGA microspheres were prepared as explained in section 3.2.3. 
 
4.2.5 Porous PLGA discs 
To create PLGA discs for in vitro experiments, 42mg of PLGA microspheres 
were mixed by hand with 63 mg of 100-350 µm salt particles for 2 minutes, and 
compressed at 1.5 tons for 2 minutes in a 6mm die using a Carver press. The discs were 
then sintered in an oven for 48 hours at the Tg for PLGA. For low-molecular weight 
PLGA, the sintering temperature was 42°C, while for high-molecular weight PLGA, the 
sintering temperature was 49°C. The sintered discs were then leached by stirring in 2 
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liters of deionized water/6 discs overnight and dried in vacuum to create porous PLGA 
scaffolds. 
To create discs with freeze-dried PEI:DNA on top, 25μl of PEI:DNA solution 
containing 1% sucrose and 10μg DNA was created/disc (Boussif, 1995). This solution 
was then added to the surface of previously sterilized scaffolds, and lyophilized overnight 
to create scaffolds with freeze-dried PEI:DNA on the surface. 
To create discs with adsorbed PEI:DNA on top, 25μl of PEI:DNA solution 
containing 1% sucrose and 10μg DNA was created/disc (Boussif, 1995). The scaffolds 
were incubated at 37°C in 10% FBS for 24 hours, and washed with PBS (Jang, 2006). 
PEI:DNA solution was then added to the surface of these scaffolds, and incubated for one 
hour at room temperature before seeding cells. 
 
4.2.6 Cell culture on tissue culture plate 
D1 cells (CRL-12424) were obtained from American Type Culture Collection. 
Cells were grown to confluence in T-75 flasks in DMEM/High Glucose medium with 
10% fetal bovine serum (FBS) (HyClone laboratories). Cells were trypsinised and seeded 
in 6 well tissue culture plates at a density of 26,000 cells/ml and 1 ml/well. In order to 
create micromass cultures, 50µl of cell suspension at a density of 30 million cells/ml was 
added to the center of each well. Five ml of medium was added/well after incubating the 
plates in 5% CO2
4.2.7 Preparation of agarose gels  
 incubator for 2 hours to allow cells to adhere on the plate. Recombinant 
human IGF-I (R&D systems) was added to the medium at 100ng/ml for the treatment 
group, and the media was changed every 2 days. At the end of experiment, wells were 
washed twice with PBS, and the cells were sonicated in 1 ml PBS for 30 seconds using 
ultrasonic processor GE-50. The cell lysates were used for DNA and GAG analysis. 
 
D1 cells were grown to confluence in T-75 flasks in DMEM/High Glucose 
medium with 10% FBS. One percent w/v agarose was autoclaved and mixed with equal 
volume of DMEM to make 0.5% agarose/DMEM solution. Cells were trypsinised and 
were added to 0.5% agarose/DMEM solution to make a final cell density of 15 million 
cells/ml. Two milliliters of agarose/DMEM/cell solution were quickly plated/well in 6 
well tissue culture plates and 5 ml DMEM was added/well. Recombinant human IGF-I 
was added to the medium at 100 ng/ml for the treatment group, and the media was 
changed every 3 days. At the end of experiment, agarose cultures were washed twice with 
PBS, and the gels were sonicated for 2 minutes using ultrasonic processor GE-50. The 
lysates were used for DNA and GAG analysis. 
 
4.2.8 Seeding of D1 cells on porous PLGA scaffolds 
D1 Cells were grown to confluence in T-75 flasks in DMEM/High Glucose 
medium with 10% FBS. One ml/well of 2% agarose was plated to the bottom of 6 well 
tissue culture plates to prevent cells from adhering to the plate surface. Porous PLGA 
scaffolds were sterilized using 70% ethanol and washed twice with PBS. Scaffolds were 
dried in a laminar flow hood overnight before seeding cells. Cells were trypsinised and 
centrifuged at 1710g in 15 ml tubes to create a cell pellet. The cell pellet was resuspended 
in 500µl of medium, and cell density was determined using a hemocytometer. Cell 
concentration was brought to 25 million cells/ml by adding additional medium. Twenty 
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five microliters of the cell suspension was added carefully to each scaffold, before 
keeping them in 5% CO2 incubator for 2 hours to allow the cells to adhere on scaffold 
surface. To create PLGA-fibrin scaffolds, cells were resuspended in serum free medium 
containing 10 mg/ml sterile fibrinogen, after centrifugation. Fifteen microliters/scaffold 
of fibrinogen-cell suspension was added to each scaffold and placed in 5% CO2 incubator 
for 30 minutes. At the end of this incubation, 15µl of 50 U/ml sterile thrombin containing 
40mM CaCl2 was added to the top of each scaffold to create fibrin clots. Scaffolds were 
then put back in the CO2 incubator for another 30 minutes. Five milliliters of DMEM was 
then added/well. Recombinant human IGF-I was added to the medium at 200 ng/ml for 
the treatment group, and the media was changed every 2 days to remove acidic 
degradation products. Cells growing on scaffolds were labeled, if needed, using 
CellTracker Green CMFDA (Invitrogen/Molecular Probes) according to the 
manufacturer’s protocol. Cells were then visualized using a Leica TCS-SP5 confocal 
microscope (Leica Microsystems). At the end of the study scaffolds were washed twice 
with PBS and transferred to 15 ml centrifuge tubes in 1ml PBS. Scaffolds were then 
sonicated for 30 seconds using an ultrasonic processor GE-50. 
 
4.2.9 Seeding of rat bone marrow cells on porous PLGA scaffolds 
Bone marrow cells were obtained from 4-6 weeks old naive Sprague-Dawley rats. 
Briefly, femurs were aseptically dissected from freshly euthanized animals. 
Intramedullary canals of femurs were then flushed with MEM Alpha modification 
medium with 10% FBS to collect bone marrow cells. Cells were transferred to T-75 
flasks and grown to confluence using MEM Alpha modification medium with 10% FBS. 
The remainder of the procedure was the same as that for D1 cells described in section 
4.2.8. 
 
4.2.10 Seeding of pig chondrocytes on porous PLGA scaffolds 
Chondrocytes were obtained by digesting cartilage from the knees of adult pig. 
Briefly, cartilage from femoral-patellar grooves of adult pig was dissected using aseptic 
techniques. The cartilage was then cut into 3mm3
Cell growth was determined by measuring the amount of DNA in the cell lysate 
using a fluorometric Picogreen® (Molecular Probes/Invitrogen) assay according to the 
manufacturer’s protocol. Calf thymus DNA was used as a standard to calculate the 
concentration of DNA from the fluorescence values. The amount of glycosaminoglycan 
(GAG) was used as an indicator of cartilage matrix synthesized on tissue culture plates, 
agarose gel and PLGA scaffolds. The amount of GAG in cell/scaffold lysate was 
determined using Blyscan® (Biocolor, UK) reagent according to the manufacturer’s 
 pieces and digested for 12 hours in 
sterile 0.3% type-I collagenase (Sigma). The cell suspension was then filtered using a 100 
µm cell strainer (BD Falcon) to remove undigested material, and centrifuged at 1710g for 
3 minutes. The cell pellet was resuspended in 500µl of serum free medium and cell 
density was determined using a hemocytometer. Cell concentration was brought to the 
required value by adding additional serum free medium. The remainder of the procedure 
was the same as that for D1 cells described in section 4.2.8. 
 
4.2.11 Analysis of cell growth and cartilage matrix synthesis 
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protocol. Chondroitin sulfate was used to create standards and calculate GAG 
concentration from absorbance values. 
 
4.2.12 In vitro IGF-I secretion 
Rat bone marrow cells were cultured for 4 weeks on PLGA scaffolds made from 
PEI:IGF-I plasmid encapsulated microspheres, and PLGA scaffolds that had freeze-dried 
PEI:IGF-I plasmid on the surface. Culture medium from this experiment was collected 
every 5 days and used for IGF-I ELISA. The amount of recombinant human IGF-I 
secreted by transfected cells was determined using RayBio® IGF-I ELISA kit 
(RayBiotech) according to the manufacturer’s protocol. Specificity of the primary 
antibody in the kit towards human IGF-I was confirmed by testing against conditioned 
medium from rat cell cultures and FBS samples. 
 
2.2.13 Statistical analysis 
Statistical analysis was performed using SAS 9.1 NC software. A p-value of 0.05 
was used for all statistical analysis. The student’s t-test or ANOVA was used for 
comparing results between different groups. Tukey-Kramer multiple comparison test was 
used post-hoc. Sample size estimation with 80% power was done using nQuery Advisor 
software. All figures show mean value +/- standard deviation for measured variable. All 
samples were in triplicate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
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4.3 RESULTS 
 
4.3.1 D1 cells cultured on tissue culture plate 
D1 cells were cultured on tissue culture plates (TCP), with the addition of 
recombinant human IGF-I in order to induce a chondrogenic phenotype in these cells. 
The results can be seen in Figures 4.2, 4.3 and 4.4. Figure 4.2 shows the amount of DNA 
at 4 days and 8 days in the IGF-I treated group and the control group, which did not have 
any IGF-I added to it. P-values for t-tests comparing the amount of DNA between control 
groups and IGF-I treated groups at either the 4 days time point or 8 days time point as 
greater than 0.05. After 5-6 days, we noticed that the cells were detaching from the 
surface of the plate after having reached confluence, especially in the IGF-I treated group 
(results not shown).  
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Figure 4.2 Amount of DNA at 4 and 8 days after seeding D1 cells on TCP 
 
The amount of GAG synthesized by the cells can be seen in Figure 4.3. IGF-I 
treated cells created 4% more GAG content compared to untreated cells at 4 days. P-
value for the t-test was greater than 0.05. At 8 days however, IGF-I treated group had 
97% lower GAG content compared to the untreated group. This difference was 
statistically significant, with a p-value less than 0.05. 
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Figure 4.3 Amount of GAG synthesized by D1 cells growing on TCP for 4 and 8 days. * 
denotes p-value < 0.05 for GAG content between control and IGF-I groups at 8 days 
 
The amount of GAG synthesized by the control and IGF-I treated groups were 
normalized to the amount of DNA in each group and plotted in Figure 4.4. The 
normalized GAG content in the IGF-I treated group was 6% more compared to the 
control group. This difference was not statistically significant, with a p-value > 0.05. At 8 
days, normalized GAG content for the IGF-I treated group was 95% lower than the 
untreated group. This difference was statistically significant, with a p-value less than 
0.05. 
* 
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Figure 4.4 Normalized GAG content for D1 cells growing on TCP for 4 and 8 days. * 
denotes p-value < 0.05 for normalized GAG content between control and IGF-I treated 
groups at 8 days 
 
4.3.2 Micromass culture of D1 cells 
D1 cells were grown as micromass cultures to study the effect of high density 
cultures on their growth and differentiation. The results are shown in Figures 4.5, 4.6, and 
4.7. Figure 4.5 shows the DNA content of D1 cells after growing for 7 and 14 days as 
micromass cultures. The DNA content for IGF-I treated and untreated groups were nearly 
identical at 7 days. At 14 days, the DNA content of IGF-I treated group was 0.9% lower 
compared to the untreated group. This difference however, was not significant with a p-
value greater than 0.05. There was significant increase in the amount of DNA from 7 to 
14 days for both the control and IGF-I treated groups (p-value < 0.05). We observed the 
detachment of IGF-I treated cells from the surface of the plate around 10-12 days. 
* 
 56 
0
0.5
1
1.5
2
2.5
3
3.5
4
Control IGF-I
D
N
A
 (µ
g/
w
el
l)
7d
14d
 
Figure 4.5 DNA content of D1 cell micromass culture at 7 and 14 days. * denotes p-value 
< 0.05 for DNA between 7 days and 14 days for both control and IGF-I groups 
 
Figure 4.6 shows the GAG content of IGF-I treated group and control group at 7 
and 14 days. P-value for t-test comparing GAG content of IGF-I treated group and 
control group after 7 days of culture was 0.055. GAG/DNA content for IGF-I treated 
group was significantly higher than the control group at 7 days as shown in Figure 4.7 (p-
value < 0.05). At 14 days, the GAG content of IGF-I treated group was 30% lower 
compared to the control group, although this difference was not statistically significant 
(p-value > 0.05). After normalizing for the amount of DNA, GAG content for the IGF-I 
treated group was 28% lower than the control group after 14 days, as shown in Figure 
4.7. This difference was not statistically significant (p-value > 0.05). 
* 
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Figure 4.6 GAG content from micromass culture of D1 cells at 7 and 14 days 
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Figure 4.7 Normalized GAG content from micromass culture of D1 cells at 7 and 14 
days.* denotes p-value < 0.05 for GAG/DNA between control and IGF-I group at 7 days 
 
4.3.3 D1 cells cultured in 0.5% agarose gel 
D1 cells were encapsulated and grown in 0.5% agarose to study the effect of 
encapsulation on growth and differentiation. The results are shown in Figures 4.8, 4.9, 
and 4.10. Figure 4.8 shows the DNA content of the control and IGF-I treated group at 1, 
* 
 58 
2 and 4 weeks of culture. DNA content for the IGF-I treated group was 5.7% and 0.5% 
higher than the control group at 1 and 2 weeks, respectively. But DNA content of IGF-I 
treated group was 14% lower than the control group at 4 weeks. These differences were 
not statistically significant (p-value > 0.05). 
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Figure 4.8 DNA content of 0.5% agarose encapsulated D1 cells at 1, 2, and 4 weeks of 
culture 
 
Figure 4.9 shows the GAG content of 0.5% agarose encapsulated D1 cells after 1, 
2 and 4 weeks of culture. IGF-I treated group had 29%, 40%, and 65% higher GAG 
content compared to the controls at 1, 2, and 4 weeks. The GAG content for the IGF-I 
treated group was significantly higher compared to the control groups at all three time 
points (p-value < 0.05). Figure 4.10 shows the normalized GAG content of the same 
cells. IGF-I treated group had 23%, 38%, and 68% higher GAG content compared to the 
controls at 1, 2, and 4 weeks. Normalized GAG content for the IGF-I treated group was 
significantly higher compared to the untreated group at all three time points (p-value < 
0.05). 
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Figure 4.9 GAG content of 0.5% agarose encapsulated D1 cells at 1, 2, and 4 weeks. * 
denotes p-value < 0.05 for GAG between control and IGF-I group at each time point 
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Figure 4.10 Normalized GAG content of 0.5% agarose encapsulated D1 cells at 1, 2, and 
4 weeks. * denotes p-value < 0.05 for GAG/DNA between control and IGF-I group at 
each time point 
 
4.3.4 D1 cells on PLGA scaffolds 
* 
* 
* 
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Figure 4.11 shows CellTracker labeled D1 cells growing at day 3 on blank 
hydrophilic PLGA scaffolds that had 20µg dsRed plasmid:PEI complexes adsorbed on 
their surface. Transfected cells are seen as red, while non-transfected cells appear green. 
Figure 4.12 shows CellTracker labeled D1 cells growing at day 8 on blank hydrophilic 
scaffolds that had 20µg dsRed plasmid:PEI complexes freeze-dried on the surface. 
Transfected cell in the center appeared red from the expressed dsRed protein. 
 
 
Figure 4.11 CellTracker labeled D1 cells growing on hydrophilic PLGA scaffolds that 
had 20µg dsRed plasmid:PEI complexes adsorbed on their surface. Transfected cells 
fluoresce red and non-transfected cells fluoresce green 
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Figure 4.12 CellTracker labeled D1 cells growing on blank hydrophilic scaffolds that had 
20µg dsRed plasmid:PEI complexes freeze-dried on the surface. Transfected cells appear 
red and non-transfected cells appear green 
 
Figure 4.13 shows CellTracker labeled D1 cells growing on PEI:DNA 
encapsulated hydrophilic PLGA scaffold after 6 days of culture. Microspheres used to 
create these scaffolds contained encapsulated dsRed:PEI complexes. Transfected cells are 
seen as red. 
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Figure 4.13 Celltracker labeled D1 cells growing on PEI:DNA encapsulated hydrophilic 
PLGA scaffold for 6 days. Scaffolds contained dsRed:PEI complexes. Transfected cells 
appear red and non-transfected cells appear green 
 
D1 cells were seeded and grown directly on blank low molecular weight 
hydrophilic PLGA scaffolds for 28 days to study the effect of soluble IGF-I on growth 
and differentiation of mesenchymal stem cells on porous scaffolds. Figure 4.14 shows the 
amount of DNA on these scaffolds at multiple time points. A time-dependent significant 
increase in DNA content from 7 to 14 to 28 days for both the control and IGF-I treated 
groups can be seen (p-value < 0.05). DNA content in the control group increased by 
120% from 7 to 14 days, and 50% from 14 to 28 days. For the IGF-I treated group these 
increases were 138% and 48%, respectively. There was, however, no significant 
difference in the DNA content between control and IGF-I treated scaffolds at any time 
point (p-value > 0.05). 
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Figure 4.14 DNA content of D1 cells growing on PLGA scaffolds at 7, 14, and 28 days. * 
denotes p-value < 0.05 for DNA between 14 days and 7 days for both control and IGF-I 
groups. + denotes p-value < 0.05 for DNA between 28 days and 14 days for both control 
and IGF-I groups 
 
Figure 4.15 shows the amount of GAG synthesized by D1 cells on PLGA 
scaffolds for up to 28 days. There was time-dependent increase in GAG content for both 
the control and IGF-I treated groups from 7 to 14 and 14 to 28 days, but these increases 
were not statistically significant (p-value > 0.05). Additionally, GAG content for IGF-I 
treated group was higher than the control group at every time point, but this difference 
was significant only for the 7 days time point (p-value < 0.05). GAG content in IGF-I 
treated group was 19% higher compared to the control group at 7 days. 
* * 
+ 
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Figure 4.15 GAG content on PLGA scaffolds at 7, 14, and 28 days after seeding with D1 
cells. * denotes p-value < 0.05 for GAG between control and IGF-I group at 7 days 
 
We saw a time-dependent decrease in normalized GAG content for both the 
control and IGF-I treated group from 7 to 14 to 28 days, as shown in Figure 4.16. This 
decrease was statistically significant for both groups. At each time point, the normalized 
GAG content for the IGF-I treated group was higher compared to the control group. 
Normalized GAG content was 34%, 17%, and 13% higher for the IGF-I treated group 
compared to the control group, at 7, 14, and 28 days respectively. The difference at 14 
days was statistically significant (p-value < 0.05). 
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Figure 4.16 Normalized GAG content for D1 cells on PLGA scaffolds at 7, 14 and 28 
days. * denotes p-value < 0.05 between control and IGF-I group at 14 days 
 
4.3.5 BMCs on PLGA scaffolds 
Rat bone marrow cells were cultured on blank hydrophilic low molecular weight 
scaffolds for 4 weeks with the addition of IGF-I to study its effect on growth and 
differentiation of these cells. Figure 4.17 shows CellTracker labeled rat BMCs growing 
on blank hydrophilic scaffold after 28 days of culture, while Figure 4.18 shows the cross 
section of a blank hydrophilic scaffold with cellTracker labeled rat BMCs growing across 
the entire cross section of the scaffold after 14 days of culture. 
 
 
Figure 4.17 CellTracker labeled rat BMCs growing on blank hydrophilic scaffold after 28 
days of culture 
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Figure 4.18 CellTracker labeled rat BMCs growing on blank hydrophilic scaffold after 14 
days of culture. T and B denote top and bottom of a discoid scaffold 
 
Figure 4.19 shows that the DNA content of IGF-I treated scaffolds was 
statistically significantly higher at 187% compared to the control group that did not 
receive IGF-I (p-value < 0.05). Similar results were seen when GAG content of these 
scaffolds were analyzed. The GAG content of IGF-I treated scaffolds were statistically 
significantly higher at 19% compared to the untreated scaffolds after 4 weeks of culture, 
as shown in Figure 4.20 (p-value < 0.05). Normalized GAG content for IGF-I treated 
scaffolds was, however, statistically significantly lower at 135% compared to the control 
scaffolds after 4 weeks of culture (p-value < 0.05). This is shown in Figure 4.21. 
T 
B 
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Figure 4.19 DNA content of BMCs growing on PLGA scaffold for 4 weeks. * denotes p 
< 0.05 
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Figure 4.20 GAG content of BMCs growing on PLGA scaffolds for 4 weeks. * denotes 
p-value < 0.05 
* 
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Figure 4.21 Normalized GAG content of BMCs growing on PLGA scaffolds for 4 weeks. 
*denotes p-value < 0.05 
 
4.3.6 D1 cells on PLGA scaffold with fibrin 
D1 cells were seeded on blank hydrophilic low molecular weight PLGA scaffolds 
and then encapsulated in fibrin glue to investigate if the fibrin glue would enhance the 
chondrogenic potential of D1 cells. Figure 4.22 shows the DNA content of IGF-I treated 
and control scaffolds at 14 and 28 days of culture. IGF-I treated scaffolds had 6.4% 
higher DNA content compared to control scaffolds at 2 weeks, and 1.7% lower DNA 
content compared to control scaffolds at 4 weeks. These differences were not statistically 
significant (p-value > 0.05). Figure 4.23 shows the GAG content from the same 
experiment. IGF-I treated scaffolds had 52% higher GAG content compared to controls 
after 2 weeks of culture, while the difference was 10.2% at 4 weeks. The difference at 2 
weeks, but not 4 weeks, was statistically significant (p-value < 0.05). 
* 
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Figure 4.22 DNA content of D1 cells growing on PLGA-fibrin scaffolds for 2 and 4 
weeks 
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Figure 4.23 GAG content of D1 cells growing on PLGA-fibrin scaffolds for 2 and 4 
weeks. *denotes p-value < 0.05 for GAG between control and IGF-I at 14 days 
 
Figure 4.24 shows the normalized GAG content for IGF-I treated and control 
PLGA-fibrin scaffolds after 2 and 4 weeks of culture. IGF-I treated scaffolds had 43% 
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and 12% higher amount of normalized GAG content compared to controls after 2 and 4 
weeks of culture. Both of these differences were statistically significant (p-value < 0.05). 
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Figure 4.24 Normalized GAG content of D1 cells growing on PLGA-fibrin scaffolds for 
2 and 4 weeks. * denotes p-value < 0.05 for GAG/DNA between control and IGF-I 
groups at both 14 and 28 days 
 
4.3.7 BMCs on PLGA scaffold with fibrin 
Rat bone marrow cells were seeded on blank hydrophilic low molecular weight 
PLGA scaffolds and then encapsulated in fibrin glue to investigate if the fibrin glue 
would enhance the chondrogenic potential of bone marrow cells. Figures 4.25, 4.26 and 
4.27 show the results from this experiment. DNA content of IGF-I treated scaffolds were 
22% higher compared to the control scaffolds, as seen in Figure 4.25. This difference was 
not statistically significant (p-value > 0.05). Figure 4.26 shows the GAG content of the 
IGF-I treated scaffolds and control scaffolds after 4 weeks of culture. GAG content of the 
IGF-I treated scaffolds were significantly higher compared to the control group, with a 
167% difference. 
* 
* 
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Figure 4.25 DNA content of BMCs growing on PLGA-fibrin scaffolds for 4 weeks 
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Figure 4.26 GAG content of BMCs growing on PLGA-fibrin scaffolds for 4 weeks. * 
denotes p-value < 0.05 
 
Figure 4.27 shows the normalized GAG content from the same experiment. 
Normalized GAG content for the IGF-I treated scaffolds were significantly higher 
compared to the control scaffolds after 4 weeks of culture (p-value < 0.05). Normalized 
GAG content for the IGF-I treated scaffolds were 119% higher compared to the control 
scaffolds. 
* 
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Figure 4.27 Normalized GAG content of BMCs growing on PLGA-fibrin scaffolds for 4 
weeks. * denotes p-value < 0.05 
 
4.3.8 Chondrocyte culture on PLGA scaffolds with fibrin 
Pig articular chondrocytes were seeded on blank hydrophilic low molecular 
weight PLGA scaffolds and then encapsulated in fibrin glue to serve as a comparison of 
cartilage matrix synthesis by already differentiated chondrocytes. Figure 4.28 shows 
CellTracker labeled pig chondrocytes growing on blank hydrophilic scaffold after 7 days 
of culture. 
* 
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Figure 4.28 CellTracker labeled pig chondrocytes growing on blank hydrophilic scaffold 
after 7 days of culture 
 
Figure 4.29 shows the DNA content of IGF-I treated and control scaffolds after 4 
weeks of culture. DNA content of IGF-I treated scaffolds were 22% higher compared to 
control group, which was not statistically significant (p-value > 0.05). 
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Figure 4.29 DNA content of pig articular chondrocytes growing on PLGA-fibrin 
scaffolds for 4 weeks 
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Figure 4.30 GAG content of pig articular chondrocytes growing on PLGA-fibrin 
scaffolds for 4 weeks. * denotes p-value < 0.05 
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Figure 4.31 Normalized GAG content of pig articular chondrocytes growing on PLGA-
fibrin scaffolds for 4 weeks. * denotes p-value < 0.05 
 
Figures 4.30 and 4.31 show the total GAG content and normalized GAG content 
of control and IGF-I treated scaffolds after 4 weeks of culture with pig chondrocytes. 
GAG content of IGF-I treated scaffolds were 117% higher compared to control group 
after 4 weeks of culture. This difference was statistically significant (p-value < 0.05). 
IGF-I treated scaffolds had 85.5% higher normalized GAG content compared to control 
group after 4 weeks of culture. This difference was also statistically significant (p-value < 
0.05). 
 
4.3.9 BMCs on plasmid-releasing scaffolds 
Rat bone marrow cells were cultured on blank hydrophilic PLGA scaffold that 
had 20µg GFP plasmid:PEI complexes freeze-dried on the surface to investigate if the 
cells would be transfected from the released plasmid. The results can be seen in Figure 
4.32. Outline of the scaffold can be seen in blue, while transfected cells are seen in green. 
 
* 
 76 
 
Figure 4.32 Rat bone marrow cells growing on blank hydrophilic PLGA scaffold that had 
20µg GFP plasmid:PEI complexes freeze-dried on the surface. Outline of scaffold is blue 
while transfected cell is green 
 
Rat bone marrow cells were then cultured on PEI:IGF-I plasmid-releasing 
scaffolds with fibrin to investigate if the cultured cells would get transfected by the 
released PEI complexed plasmid, express IGF-I protein and then differentiate towards a 
chondrocytic lineage. Three different types of plasmid releasing scaffolds were 
fabricated. Low molecular weight hydrophilic microspheres with encapsulated PEI:DNA 
complexes were used to make the scaffolds. In addition, blank scaffolds with freeze-dried 
plasmid on the surface, and scaffolds with both encapsulated and freeze-dried plasmid 
(dual) were also tested. 
Figure 4.33 shows the secretion profile of rhIGF-I from different BMC seeded 
scaffolds up to 20 days of culture. IGF-I was detected in the supernatant from day 2 for 
all the groups. Highest concentration of 320pg/ml IGF-I was detected from PEI:IGF-I 
plasmid encapsulated scaffolds on days 9 and 14 after seeding the cells. Secreted IGF-I 
levels from encapsulated scaffolds were statistically significantly higher than freeze-dried 
and dual groups on days 9 and 14. Differences in secreted IGF-I concentration between 
PEI:IGF-I plasmid encapsulated scaffolds and blank scaffolds were not statistically 
significant at any time point, with a p-value of 0.07 on day 9. Sample size of four/group 
was needed to get p-value < 0.05 with 80% power. IGF-I levels started decreasing for all 
groups starting at day 14.  
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Figure 4.33 rhIGF-I secretion profile from BMC culture on IGF-I plasmid-releasing 
PLGA scaffolds 
 
Figure 4.34 shows the DNA content on similar IGF-I plasmid-releasing scaffolds 
after culturing rat bone marrow cells for 4 weeks. Blank scaffolds and dual scaffolds had 
the lowest amount of DNA content at weeks. Highest DNA content was found on 
plasmid encapsulated scaffolds. The difference in DNA content among the different 
groups was not statistically significant (p-value > 0.05). 
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Figure 4.34 DNA content of BMCs growing on IGF-I plasmid-releasing scaffolds for 4 
weeks 
 
GAG content on the different scaffolds are shown in Figure 4.35. The lowest 
amount of GAG was detected in the blank scaffolds. IGF-I plasmid encapsulated 
scaffolds had 6% higher GAG content compared to blank scaffolds. Scaffolds with IGF-I 
plasmid freeze-dried on the surface had 15.3% higher GAG content compared to blank 
scaffolds, and scaffolds that had both encapsulated and freeze-dried plasmid had 20% 
higher GAG compared to blank scaffolds. None of these differences were statistically 
significant (p-value > 0.05). 
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Figure 4.35 GAG content on IGF-I plasmid releasing scaffolds after 4 weeks of culture 
with BMCs 
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Figure 4.36 Normalized GAG content on IGF-I plasmid-releasing scaffolds after 4 weeks 
of culture with BMCs 
 
Figure 4.36 shows the normalized GAG content on IGF-I plasmid-releasing 
scaffolds after 4 weeks of culture with rat BMCs. Plasmid encapsulated scaffolds had the 
lowest normalized GAG content among all groups. Scaffolds with both encapsulated and 
freeze-dried plasmid had the highest normalized GAG content. Scaffolds with freeze-
dried IGF-I plasmid as well as scaffolds with both freeze-dried and encapsulated IGF-I 
plasmid had significantly higher normalized GAG content compared to scaffolds with 
encapsulated IGF-I plasmid. P-value for the ANOVA comparing the normalized GAG 
content between different groups was greater than 0.05. 
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4.4 DISCUSSION 
 
4.4.1 D1 cells on tissue culture plate 
D1 cells are mesenchymal multipotent cells, originally isolated from mouse bone 
marrow, and have been shown to have osteogenic and adipogenic potential (Diduch, 
1993). After culture on tissue culture plates, DNA content in the control and IGF-I treated 
groups were similar at both 4 days and 8 days time point. We observed that the cells were 
detaching from the plate after reaching confluence. The time to reach confluence was 
hastened when IGF-I was added to the medium. IGF-I treated group had higher GAG and 
normalized GAG content at 4 days, although this difference was not statistically 
significant. We expected this difference to increase with time, but on the contrary, GAG 
content decreased for the IGF-I treated group with time. Limited area for the cells to 
proliferate on 6 well tissue culture plates was interfering with the experimental design. 
Comparison of total GAG and normalized GAG content after 8 days of culture showed 
that IGF-I treated group had lower values than the controls. This was probably due to the 
sloughing off of cells in the IGF-I treated group around 6 days, removing the newly 
synthesized GAG with them. Expansion of articular chondrocytes as monolayer culture 
has been shown to decrease collagen-II and aggrecan production previously (Binette, 
1998). This is an indication of dedifferentiation of chondrocytes, as they are cultured on a 
two-dimensional surface rather than their native three-dimensional matrix. 
It has been reported previously that chondrogenic differentiation of adult 
mesenchymal stem cells on monolayer culture is dependent on seeding density (Takagi, 
2007). This was thought to be due to higher amounts of cytokines produced by the cells 
acting in a paracrine mechanism, and aiding their differentiation (Takagi, 2007). We 
cultured high density micromass cultures of D1 cells on tissue culture plates to study the 
effects of high seeding density on chondrogenic differentiation of D1 cells. The amount 
of DNA in control and IGF-I treated groups were similar at 7 days, and again at 14 days. 
But the DNA content increased significantly for both the control and IGF-I treated groups 
from 7 to 14 days, as the cells proliferated on the plate surface. Total GAG and 
normalized GAG were significantly higher for the IGF-I treated group compared to 
controls at 7 days, but surprisingly, were lower than the controls at 14 days. This can 
again be explained by the observation that around days 10-12 IGF-I treated cells reached 
confluence and sloughed off from the plate surface. Culturing embryonic mesenchymal 
cells on tissue culture plate at high density has shown a time-dependent increase in 
cartilaginous matrix production (Mello, 1999). Micromass culture of murine multipotent 
cells C3H10T1/2 on tissue culture plate with Ham’s F12 medium and BMP-2 resulted in 
chondrocytes-like cells with high collagen-II and sulfate content (Denker, 1999). In our 
experiment, loss of extracellular matrix resulted in lower GAG content in the IGF-I 
treated group compared to the controls by 14 days. Differences in cell type and culture 
conditions might have resulted in different results in our case compared to other high 
density micromass cultures on TCP. 
 
4.4.2 Agarose gel culture of D1 cells 
It has been reported previously that dedifferentiated chondrocytes revert to the 
differentiated form when cultured in 0.5% agarose gel (Benya, 1982). It was suggested 
that this reversion was primarily due to the return of chondrocytes to their native round 
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morphology in suspension culture (Benya, 1982). Mesenchymal stem cells embedded in 
agarose have been used to treat growth plate injury model in rabbits with resultant 
correction of angular deformity and limb length inequality (Chen, 2003). We cultured D1 
cells in 0.5% agarose gel with the addition of IGF-I for 28 days to study the effect of 
anchorage-independent culture on chondrocytic differentiation of mesenchymal cells. We 
did not see much difference in DNA content of the cultures from7 to 14 to 28 days. There 
was an 18% increase in DNA content of the control group from 14 to 28 days, but this 
was not statistically significant. DNA content of control and IGF-I treated groups were 
similar at all time points. The lack of increase in DNA content over time could be from 
the physical constraint of being encapsulated in a 3D matrix, as well as from switching to 
a differentiation phase from proliferative phase. Both GAG and normalized GAG showed 
statistically significant increase from 7 to 14 days in both the control group and IGF-I 
treated group. More importantly, GAG and GAG/DNA values were significantly higher 
for the IGF-I treated group at all three time points. The difference in GAG and 
GAG/DNA values between the control group and IGF-I treated group increased with 
time. All these observations suggest that 0.5% agarose gel culture of D1 cells resulted in 
cartilage matrix synthesis, and this matrix synthesis was significantly higher when treated 
with IGF-I. These results are similar to the reported collagen-II and proteoglycan 
synthesis by dedifferentiated chondrocytes when grown in 0.5% agarose gel (Benya, 
1982). 
 
4.4.3 D1 cells on PLGA scaffolds 
Mesenchymal stem cells have been cultured on three dimensional scaffolds in 
order to create cartilaginous matrix (Kafienah, 2007; Farrell, 2006). Adult rat 
mesenchymal stem cells grown on collagen-glycosaminoglycan scaffolds with the 
addition of dexamethasone and TGF-1β resulted in increased collagen-II production 
(Farrell, 2006). Mesenchymal stem cells dispersed in collagen gel have been used to 
repair full thickness chondral defects (Wakitani, 1994). Mesenchymal stem cells seeded 
on poly(glycolic acid) scaffold with the addition of retinoic acid inhibitor resulted in 
cartilage synthesis, as determined histologically (Kafienah, 2007).  
Hydrophilic PLGA scaffolds created by us supported the growth and transfection 
of D1 cells from released PEI complexed plasmids. Cells were seen growing along the 
entire thickness of the scaffold after 14 days of culture. Culturing D1 cells on blank 
scaffolds resulted in significant cell proliferation up to 28 days, as shown by significant 
increases in DNA content from 7 to 28 days for both control and IGF-I treated groups. 
There was an increase in the amount of GAG produced by D1 cells grown on blank 
scaffolds from 7 to 28 days with and without IGF-I, although the increase was not 
statistically significant. Because the DNA content of the scaffolds increased at a faster 
rate than the GAG content, we saw a decrease in GAG/DNA content from 7 to 14 to 28 
days for both the control and IGF-I treated group. It appears that the cells continued to 
proliferate rather than differentiate after seeding on PLGA scaffolds. Mesenchymal stem 
cell cultured on PLGA scaffolds with TGF-β1 and dexamethasone showed significant 
increase in DNA content from 2 to 4 weeks, but the increase in total GAG was not 
significant (Park, 2009). When mesenchymal stem cells were seeded on PLLA scaffolds 
and grown for 42 days in spinner culture with the addition of TGF-β1 and IGF-I, 
significant increase in GAG/DNA content was observed from 14 to 42 days (Janjanin, 
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2008). But DNA content in the same culture did not increase during the same time 
period. The physical constraint of growing on PLLA scaffolds that were compressed 
between two polypropylene discs might have pushed the cells into a differentiation phase 
instead of a proliferative phase, resulting in the synthesis of cartilaginous matrix. 
Culturing mesenchymal stem cells on collagen-PLGA mesh with TGF-β3 resulted 
in collagen II and aggrecan mRNA upregulation after 4 weeks, but GAG and collagen II 
was expressed in significant amounts only by 10 weeks of culture (Chen, 2004). When 
mesenchymal cells were cultured on PLGA scaffolds with the addition of TGF-β3, GAG 
secretion started to increase after 17 days of culture (Lee, 2004). These studies 
demonstrate the incubation period needed for mesenchymal cells to differentiate and 
synthesize cartilaginous matrix on PLGA matrices in chondrogenic media. 
It is possible that the duration of our experiment was not sufficient for detecting 
significant differences in GAG content between the IGF-I treated and control groups, as 
the cells continued to be in the proliferative phase 4 weeks after culture. But there was a 
clear pattern of higher GAG content for the IGF-I treated group at every time point, and 
the difference would have become significant as the mesenchymal stem cells 
differentiated and synthesized significant amounts of extracellular matrix. 
 
4.4.4 BMCs on PLGA scaffolds 
Bone marrow cells have been shown to be particularly useful in tissue engineering 
because of their superior proliferation and matrix production (Eijk, 2004). Human bone 
marrow stromal cells cultured in alginate-collagen II capsules showed large regions of 
cell generated matrix (Pound, 2007). Human bone marrow cells cultured using a rotating 
wall bioreactor without any growth factors showed significant GAG synthesis at 2 weeks 
(Sakai, 2009), while human bone marrow stromal cells grown on silk scaffolds with 
TGF-β1, insulin, and dexamethasone in a rotating bioreactor showed significantly higher 
GAG/DNA content compared to control scaffolds without chondrogenic growth factors 
(Marolt, 2006). These studies demonstrate the chondrogenic potential of bone marrow 
stromal cells in various chondrogenic media and three dimensional matrices. 
In our study, rat bone marrow cells seeded on hydrophilic PLGA scaffolds 
continued to grow until 28 days, when the scaffolds were degraded extensively. When 
these cells were seeded with the addition of IGF-I to the culture medium, we saw 
significantly higher DNA and GAG contents in the IGF-I treated scaffolds compared to 
the untreated controls. Normalized GAG content however, was significantly lower 
compared to the control group. The lower GAG/DNA content for the IGF-I treated group 
compared to control was because of the much higher DNA content in the IGF-I treated 
group compared to the untreated group. It appears that IGF-I acted as a strong mitogen, 
driving the proliferation of seeded cells in the treated scaffold, along with synthesis of 
extracellular GAG. Critical factors in chondrogenesis from bone marrow-derived 
progenitor cells are high cell density and cell-cell interaction (Johnstone, 1998; Yoo, 
1998). Mesenchymal stem cells growing on three dimensional scaffolds still involve 
surface contacts similar to monolayer culture, and are likely to inhibit differentiation 
(Murdoch, 2007). IGF-I during the initial periods of culture would not have aided in the 
differentiation of seeded bone marrow cells until they reached the critical density, after 
which they would have driven differentiation and enhanced synthesis of extracellular 
matrix proteoglycans such as GAG. This initial lag would have shortened the effective 
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duration for chondrogenic action of IGF-I in our experiment, and led to lower GAG/DNA 
content for the treated scaffolds compared to the control group at 4 weeks. 
 
4.4.5 PLGA-fibrin scaffolds 
Fibrin is a natural polymer formed as the end result of the blood coagulation 
cascade, and can be expected to form at the implant site as blood from surrounding bone 
infiltrates the implanted porous scaffold. Suspending cells in fibrin prior to seeding them 
on porous scaffolds can minimize cell-loss during the addition of culture medium, as the 
cells get clotted inside the pores. Fibrin-cell suspension has also been shown to lead to a 
homogenous distribution of cells in porous scaffolds (Zheng, 2006). Porous PLGA 
scaffolds have been used previously for chondrogenesis by seeding chondrocytes-fibrin 
suspension (Munirah, 2008). In that study, significant cartilage tissue was synthesized as 
early as 2 weeks, and collagen II and aggrecan mRNA were expressed. PLGA-fibrin 
scaffolds had significantly higher GAG content compared to PLGA scaffolds with 
chondrocytes alone at 3 weeks (Munirah, 2008). Subcutaneous implantation of PLGA-
fibrin scaffolds seeded with chondrocytes in mice resulted in significantly higher GAG 
content after 2 weeks of implantation (Munirah, 2008b). 
We seeded hydrophilic PLGA scaffolds with D1 cells and BMCs suspended in 
fibrinogen, and then clotted them using thrombin-CaCl2 solution to study the benefit of 
using PLGA-fibrin scaffolds in chondrogenesis. DNA content of PLGA-fibrin scaffolds 
seeded with D1 cells increased significantly from 2 to 4 weeks for both the control group 
and IGF-I treated group. There was no significant difference in DNA content between the 
control and IGF-I treated group at either 2 or 4 weeks. Total GAG content was 
significantly higher for IGF-I treated group compared to control group at 2 weeks, but the 
difference was not significant at 4 weeks, although IGF-I treated group had 16% higher 
GAG compared to the control group. Interestingly, there was little change in total GAG 
content from 2 to 4 weeks for the IGF-I treated group, while there was significant 
increase for the control group. It appears that most of the GAG synthesis in the IGF-I 
treated group happened in the first 2 weeks of culture. Actions of feedback mechanisms 
might explain this apparent lack of response to growth factor later in culture. Cytokine 
production after TGF-β receptor activation has been shown to suppress further cellular 
response to TGF-β (Fromigue, 1998). In our study, GAG/DNA was significantly higher 
at both 2 weeks and 4 weeks in the IGF-I treated group compared to the control groups. 
This indicates that the seeded cells had differentiated to a chondrogenic phenotype, and 
were synthesizing cartilaginous extracellular matrix. This was in contrast to the D1 cell 
culture without fibrin when the difference in GAG/DNA content between the IGF-I 
treated group and control group was not significant at 4 weeks. Similar results were seen 
when chondrocytes were cultured with and without fibrin on PLGA scaffolds, and was 
ascribed to the higher seeding efficiency and homogenous cell distribution in fibrin-
PLGA cultures compared to non-fibrin PLGA scaffolds (Munirah, 2008). Culturing 
mesenchymal stem cells on fibrin-polyurethane scaffolds with the addition of TGF-β1 
and dexamethasone has shown comparable GAG/DNA to pellet cultures with higher 
collagen II and aggrecan gene expression (Li, 2009). Suspending chondrogenic cells in 
fibrin prior to seeding has the advantages of increasing the cell density in scaffolds, 
ensuring that the cells remain in the scaffold, as well as encapsulating the cells in a true 
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three dimensional matrix, all of which have been previously shown to be beneficial to 
chondrogenesis. 
Seeding BMCs on PLGA scaffolds with fibrin showed the most difference in 
GAG production between IGF-I treated and control scaffolds among all the cell-scaffold 
combinations investigated by us. There was no significant difference in DNA content 
between IGF-I treated and control scaffolds, but IGF-I treated scaffolds had 167% higher 
GAG content compared to controls after 4 weeks of culture. IGF-I treated scaffolds had 
119% higher GAG/DNA content compared to controls after 4 weeks. Similar to the 
results we saw for D1 cells with and with out fibrin, BMCs seeded with fibrin responded 
much differently compared to the BMCs that were seeded directly on PLGA scaffolds. 
All the reasons that we mentioned above for the successful chondrogenesis using D1 cells 
with fibrin-PLGA scaffolds compared to PLGA alone apply to BMCs also. In addition, 
the robust response to IGF-I by BMCs might be due to their low passage number 
compared to D1 cells used in our experiment. Monolayer expansion of chondrocytes after 
passage 5 has been shown to lead to their dedifferentiation and lack of collagen II and 
GAG synthesis when cultured on scaffolds in vitro (Kang, 2007). Similarly, it has been 
shown that mesenchymal stem cells can be expanded in monolayer cultures until passage 
5 without losing their undifferentiated phenotype (Cournil-Henrionnet, 2008). D1 cells 
were originally isolated from mouse bone marrow, and have been shown to have 
osteogenic and adipogenic potential (Diduch, 1993). D1 cells used in our experiments 
were from passage 26 or later, and it is possible that these cells had dedifferentiated and 
become less responsive to IGF-I compared to the BMCs that were from passage 1. 
 
4.4.6 Chondrocytes on PLGA-fibrin scaffolds 
Rabbit articular chondrocytes have been seeded with fibrin glue in PLGA 
scaffolds, with resultant production of a cartilaginous matrix as early as 2 weeks 
(Munirah, 2008). These scaffolds had significantly higher GAG content compared to 
PLGA scaffolds that were seeded with articular chondrocytes without fibrin (Munirah, 
2008). Implantation of these scaffolds in athymic nude mice also showed significantly 
higher GAG content after 2 weeks compared to PLGA scaffolds without fibrin (Munirah, 
2008b). Fibrin glue with gelatin/hyaluronic acid/chondroitin sulphate copolymer has been 
used for neocartilage formation using porcine chondrocytes (Chou, 2007). 
Gelatin/hyaluronic acid/chondtroitin sulfate copolymer was added to fibrin glue to 
improve the mechanical properties of an otherwise soft fibrin gel, to withstand forces 
experienced by articular surfaces (Chou, 2007). 
We seeded porcine articular chondrocytes into fibrin-PLGA scaffolds, and 
cultured them for 4 weeks with the addition of IGF-I. Seeded chondrocytes were seen 
growing along the surface of the scaffold after 7 days. There was no significant 
difference in the DNA content of IGF-I treated scaffolds and control scaffolds, but both 
GAG and GAG/DNA contents were significantly higher in the IGF-I treated group after 4 
weeks of culture. Not surprisingly, these scaffolds also had the highest GAG and 
GAG/DNA content among all the cell-fibrin-PLGA scaffolds we tested. Since 
chondrocytes are already differentiated cells, any added IGF-I to the media can lead to an 
increase in GAG content, as the cells proliferate and populate the porous scaffolds. An 
increase in cell number would also have lead to an increase in associated matrix 
components such as GAG. Chondrocytes grown in fibrin cultures with exogenous IGF-I 
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have been shown to increase cell proliferation and proteoglycan synthesis (Fortier, 1999). 
The cumulative effect of using well differentiated cells such as chondrocytes with a 
chondrogenic growth factor, such as IGF-I, might be the reason for high GAG and 
GAG/DNA content for chondrocyte-fibrin-PLGA cultures. 
 
4.4.7 BMCs on IGF-I plasmid-releasing scaffolds 
Rat bone marrow cells were cultured on IGF-I plasmid releasing scaffolds to 
investigate if the cultured cells would get transfected by the released the PEI complexed 
plasmid, express IGF-I protein and then differentiate towards a chondrocytic lineage. 
Previous studies have shown that ex vivo transfer of IGF-I DNA into chondrocytes can 
enhance chondrogenesis in vitro and in vivo (Madry, 2002; Madry, 2005). Cationized 
gelatin nanoparticles have been used to deliver IGF-I plasmid to canine articular 
chondrocytes in vitro, which resulted in transfection and release of IGF-I protein from 3 
to 12 days into the culture medium (Xu, 2008). When these transfected cells were seeded 
on collagen-GAG scaffolds, there was significantly higher GAG/DNA amount compared 
to control scaffolds with untransfected chondrocytes (Xu, 2008). Mesenchymal cells 
infected with AdIGF-I, and suspended in fibrin glue has been used for successful repair 
of articular cartilage (Gelse, 2003). 
In our study, significant production of IGF-I was observed only for the PEI:IGF-I 
plasmid encapsulated scaffolds. These scaffolds produced a peak concentration of 320 
pg/ml IGF-I on days 9 and 14. The p-value for the difference in secreted IGF-I between 
plasmid encapsulated and blank scaffolds was 0.07, suggesting that we narrowly missed 
statistical significance. Increasing the number of samples per group might be able to 
bring out the statistical significance in this case. Chondrocytes seeded on collagen-GAG 
scaffolds that had lipid-complexed IGF-I plasmid crosslinked on the surface showed peak 
IGF-I production of 2500pg/ml on day 14 (Capito, 2007). The differences in cell type as 
well as plasmid carrier could account for this difference in secreted IGF-I concentration. 
The highest concentration of IGF-I produced from our scaffolds were 1000 times lower 
than the concentration of IGF-I used as a medium supplement for chondrogenesis in our 
experiments. However, it is possible that the local concentration of IGF-I around 
transfected cells within the scaffold be much higher than the concentration in the culture 
medium. Significant chondrogenesis was reported with IGF-I plasmid-transfected 
chondrocytes on collagen-GAG scaffolds, although these cells produced IGF-I at a 
concentration of 2000-2500pg/ml in the culture medium (Xu, 2008). Interestingly, 
scaffolds with freeze-dried PEI:IGF-I plasmid on the surface alone and in combination 
with encapsulated PEI:IGF-I plasmid failed to produce any significant amounts of IGF-I. 
It is possible that the high concentration of freeze-dried PEI:DNA particles on the surface 
of these scaffolds led to their aggregation into larger particles, making it difficult or 
impossible for the cells to internalize them and get transfected. The surface coating of 
PEI:DNA particles could also have interfered with the cell adhesion process, effectively 
decreasing the initial number of cells on the scaffold and IGF-I produced, compared to 
blank and plasmid encapsulated scaffolds. A decrease in the amount of protein expressed 
has been noted with very high PEI:DNA loading of PLGA scaffolds, and was speculated 
to be due to aggregation of PEI:DNA particles and sequestration of DNA, making it less 
accessible for gene transfer (Huang, 2003). It is also possible that the freeze-dried 
PEI:DNA particles might be interacting with the PLGA polymer, slowing their release to 
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the cells for transfection. Only 40% of adsorbed PEI:DNA particles were released at the 
end of 4 days of release from PLGA scaffolds (Jang, 2006). We saw a small amount of 
IGF-I produced from blank scaffolds that had BMCs seeded on them. Similar production 
of small amounts of IGF-I was seen when assaying for IGF-I after canine chondrocytes 
were seeded on collagen-scaffolds (Capito, 2007). This small amount of IGF-I might be 
due to the constitutive expression of rat IGF-I from bone marrow cells crossreacting with 
the human IGF-I antibody in our assay.  
We saw increased cell proliferation on IGF-I plasmid encapsulated scaffolds 
when rat bone marrow cells were cultured on IGF-I plasmid releasing PLGA scaffold 
with fibrin. DNA content of IGF-I plasmid encapsulated scaffolds were approximately 
38% higher than other groups of scaffolds, although this difference was statistically 
insignificant with a p-value of 0.07. We had seen peak IGF-I release from the IGF-I 
plasmid encapsulated scaffold around 350pg/ml on days 10-12. The low concentration of 
IGF-I along with the delay in getting the IGF-I into the culture medium by the transfected 
cells would have effectively shortened the exposure of seeded cells to IGF-I when the 
culture was ended at 4 weeks. There were no significant differences in the total GAG 
content between blank scaffolds and other IGF-I plasmid releasing scaffolds at 4 weeks, 
although blank scaffolds had the least amount of total GAG among the different groups. 
The decreased exposure of cells to IGF-I produced by transfected cells might have been 
the reason for this result. When comparing GAG/DNA content between scaffolds, 
plasmid encapsulated scaffolds had the lowest value among the groups. This was not 
surprising because of the high DNA content of these scaffolds, which naturally decreased 
the GAG/DNA ratio. GAG/DNA contents among the other scaffold groups were 
statistically similar. To our surprise, scaffolds that had 10µg PEI:DNA complexes freeze-
dried on the surface fared poorly in both DNA and GAG contents compared to control 
and PEI:DNA encapsulated scaffolds. When canine chondrocytes were seeded on 
collagen-GAG scaffolds with freeze-dried lipid:DNA complexes on the surface, similar 
decrease in DNA content was observed after 2 weeks of culture (Capito, 2007). It was 
speculated that the surface coating of lipid:DNA complexes might have inhibited cell 
attachment and proliferation on these scaffolds, leading to low DNA content. Surface 
coating of sucrose and PEI:DNA particles on our scaffolds with freeze-dried PEI:DNA 
complexes could have had the same inhibitory effect.  
Scaffolds made of high molecular weight PLGA with encapsulated IGF-I plasmid 
can increase the exposure of cells to secreted IGF-I by releasing the plasmid longer, and 
degrading at a slower rate. This increase in exposure might result in significant 
chondrocytic differentiation of mesenchymal progenitor cells grown on such scaffolds. 
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4.5 CONCLUSION 
 
Agarose cultures of D1 cells were able to show differentiation to a chondrocytic 
phenotype as evidenced by increased total GAG and GAG/DNA contents. Our porous 
PLGA scaffolds supported the growth and differentiation of D1 cells, chondrocytes and 
bone marrow cells in vitro. Suspension of cells in fibrin prior to seeding resulted in 
significant differences in total GAG and GAG/DNA contents between IGF-I treated and 
control groups for mesenchymal stem cells, bone marrow cells and chondrocytes, where 
as the differences were not significant when cultured on scaffolds without fibrin. This 
proved that fibrin was critical in the differentiation of the cells into chondrogenic 
phenotype, probably by retaining seeded cells within the scaffold and thus increasing cell 
density, as well as encapsulating the cells in a three dimensional environment. Among the 
three cells types studied, chondrocytes had the highest GAG/DNA content after 4 weeks 
of culture, where as bone marrow cells showed the largest difference in GAG/DNA 
between IGF-I treated and control groups. Culturing BMCs on IGF-I plasmid 
encapsulated scaffolds resulted in elevated expression of rhIGF-I compared to blank and 
IGF-I plasmid freeze-dried scaffolds. Although the amount of IGF-I produced was not 
statistically significant compared to controls, the p-value was 0.07, suggesting that 
increasing the number of samples can make the difference statistically significant. Bone 
marrow cells cultured on the IGF-I plasmid encapsulated scaffolds showed the highest 
DNA content among all the groups. Total GAG was higher for all plasmid-releasing 
scaffolds compared to the blank scaffolds, but these differences were not statistically 
significant. Low concentration of IGF-I released from transfected cells along with the 
delay in its production might have been the reason for the inability to observe significant 
chondrocytic differentiation in bone marrow cells seeded on IGF-I plasmid-releasing 
scaffolds. Using scaffolds made from higher molecular weight hydrophilic PLGA to 
culture cells, along with increasing the amount of IGF-I secreted can increase the 
exposure of cells to IGF-I, and might result in successful chondrogenesis using bone 
marrow progenitor cells. 
 88 
5. IGF-I PLASMID-RELEASING PLGA SCAFFOLDS FOR GROWTH PLATE 
REGENERATION IN VIVO 
 
5.1 INTRODUCTION 
Growth plate injuries account for approximately 15% to 30% of all fractures of 
long bones in children (Mizuta, 1987). About 10% of these will result in significant 
growth disturbances due to the formation of a boney bar (Salter, 1994). This boney bar 
can act as a tether, attaching the epiphyseal bone to the diaphyses, and limiting the 
continued normal growth of the limb. If not treated correctly, this can lead to life lasting 
consequences of limb length inequalities and angular deformities. Most cases of growth 
arrest from the formation of boney bars occur during early adolescence because this is 
when the growth plate is thickest and weakest (Khoshhal, 2005). If the physeal fracture 
occurs at the periphery of long bones, angular deformity can result, whereas a centrally 
located physeal fracture can lead to metaphyseal tenting and damage to articular surface 
(Khoshhal, 2005). It has been postulated that cellular disruption and ischemia resulting 
from a fracture might be the mechanism of growth plate injury (Khoshhal, 2005). 
Surgical resection of a boney bar is indicated only if the injury involves less than 50% of 
the growth plate, and the patient has more than 2 years of growth remaining. The chances 
of success are greater for younger patients and smaller boney bridges (Khoshhal, 2005). 
Use of an interpositional material after resection of the boney bar was first 
reported by Langenskiöld, who used fat to fill the defect, using an approach now called 
the Langenskiöld technique (Langenskiöld, 1967). Current treatments for growth plate 
injuries include removal of boney bar, and insertion of fat, silicone, bone cement etc to 
replace the growth plate. These treatment modalities are inadequate, leaving almost half 
of these patients with continued deformities (Hasler, 2002). 
Tibiae that received fat as interpositional material in a rabbit growth plate injury 
model developed severe varus and failed to grow in length (Lee, 1993). But this is in 
contrast to what was reported by Langenskiöld, whose patients benefited from fat grafts 
to treat growth plate arrest (Langenskiöld, 1987). Implantation of silastic in a rabbit 
model of growth plate injury resulted in less angular deformity and length discrepancy 
during the first few weeks after surgery, but this was lost 12 weeks after surgery (Lee, 
1993). Implantation of an iliac physeal transplant showed the least varus and length 
discrepancy at 12 weeks after surgery (Lee, 1993). But this would necessitate a second 
surgical site, removal of healthy tissue with its associated risks and scarring at the donor 
site. Another material that has been used a graft to replace the physis is poly(methyl 
methacrylate) polymer, which is not biodegradable (Klassen, 1982). Implantation of an 
atelocollagen gel embedded with autologous chondrocytes resulted in significantly lower 
varus and length discrepancy 52 weeks after surgery in a rabbit model of physeal injury 
(Tobita, 2002). This technique would also require harvesting healthy articular 
chondrocytes, which can lead to other articular cartilage problems.  Implantation of 
mesenchymal stem cells embedded in agarose gel in a rabbit physeal injury model 
resulted in correction of varus deformity and limb length discrepancy (Chen, 2003). 
When agarose embedded chondrocytes were implanted in a rabbit model of physeal 
injury, only mild varus deformity and limb length discrepancies were seen (Lee, 1998).  
Although implantation of scaffolds with embedded autologous cells have shown 
positive results, the technique has the disadvantages of donor site scarring, and the need 
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for a harvest procedure. When applying this technique to humans, it also requires that the 
treatment be tailored to individual patients. The stem cells or chondrocytes will have to 
be harvested and multiplied to sufficient numbers before they can be incorporated into 
scaffolds and readied for implantation. This can significantly increase the cost of 
treatment. An interpositional material that can regenerate native growth plate by releasing 
chondrogenic growth factors, match the mechanical properties of cartilage, and degrade 
at an appropriate rate will be superior to one that incorporates cells prior to implantation. 
Previous chapters of this dissertation have presented the development of porous PLGA 
scaffolds that can release naked and PEI-complexed DNA in a controlled manner, and 
that culturing chondrocyte-progenitor cells on these scaffolds with IGF-I can lead to 
significant synthesis of cartilage in vitro. This chapter of my dissertation presents the in 
vivo trial of IGF-I plasmid-releasing porous PLGA scaffolds in a rabbit model of growth 
plate injury. 
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5.2 MATERIALS AND METHODS 
 
5.2.1 Preparation of porous PLGA scaffolds 
Blank and PEI:IGF-I-plasmid encapsulated hydrophilic PLGA microspheres were 
prepared as described in chapter 1. To create PLGA discs for implantation, 120 mg of 
PLGA microspheres were hand-mixed with 180 mg of salt particles for 2 minutes, and 
compressed at 7 tons for 2 minutes in a 13 mm die using a Carver press. The discs were 
then sintered in an oven for 48 hours at 42°C. The sintered discs were then leached in 
deionized water overnight and dried in vacuum to create porous PLGA scaffolds. These 
scaffolds were then sterilized using 70% ethanol prior to implantation. To create 
scaffolds with freeze-dried and encapsulated IGF-I plasmid, 15µg of PEI:DNA complex 
was freeze-dried on to the surface of IGF-I plasmid encapsulated scaffolds. 
 
5.2.2 Animal Surgery 
Six to eight weeks old New-Zealand white rabbits were used in our study. 
Animals were anesthetized and radiographic images of hind limbs were taken prior to 
inducing growth plate injury. Incision was made on the anteromedial side of tibia, and 
medial tibia was exposed. Figure 5.1 shows the intact growth plate as a thin white line. 
Medial half of the tibial growth plate was removed using a 1 mm burr (Stryker Medical). 
Incision was closed using sutures after thorough irrigation. This procedure was repeated 
on the contralateral limb. Animals were allowed to recover in their pens. 
Three weeks after the growth plate injury, animals were brought back for the 
implantation of PLGA scaffolds. Radiographic images of hind limbs were taken to 
confirm growth plate injury and formation of the boney bar. Figure 5.2 is a radiograph of 
the lower hind limbs taken 3 weeks after the growth plate was removed. Increased 
radioopacity, indicating formation of bone, can be seen in the medial halves of tibia 
bilaterally (arrows), while the lateral growth plate can be seen to be intact.  Medial 
proximal tibia was exposed through an anteromedial incision. Boney bar was removed 
using a burr. Blank or IGF-1 DNA loaded disk was inserted into the defect. Incision was 
closed after thorough irrigation. For the control legs, boney bar was resected and nothing 
was implanted in the defect. Figure 5.3 shows the implantation of a hydrophilic scaffold 
that has been placed into the defect after removal of the boney bar. The scaffold is then 
trimmed to the size of the defect to create a good fit and inserted into the defect, as shown 
in Figure 5.4. 
Animals were returned to their pens, and allowed to heal for 8 or 16 weeks. At the 
end of eight or sixteen weeks, animals were euthanized. Radiographic images of hind 
limbs were taken, and lower hind limbs harvested for further analysis. Figure 5.5 
illustrates the experimental design. Implantation of scaffolds was randomized such that 
no animal received the same type of scaffold in both legs. 
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Figure 5.1 Intact tibial growth plate of New Zealand white rabbit 
 
 
Figure 5.2 Radiograph of rabbit lower hind limbs 3 weeks after surgery to remove medial 
tibial growth plate. Arrows indicate boney bars 
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Figure 5.3 Scaffold being inserted into medial tibia  
 
 
Figure 5.4 Hydrophilic scaffold in medial tibia 
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Figure 5.5 Experimental design 
 
5.2.3 Morphometry 
Medial and lateral lengths of tibiae were measured using a digital caliper (Fisher 
scientific Model No. 14-648-17) for each lower hind limb. Widths of fibulae were also 
measured. 
Radiographic images were analyzed using Scion Image software. Medial 
proximal tibial angle (MPTA) and lateral distal femoral angle (LDFA) were measured for 
each lower hind limb. Measurements were done twice on each image by a single 
examiner. Medial proximal tibial angle is the internal angle formed between the shaft of 
tibia and top of the tibia. Lateral distal femoral angle is the internal angle 
formed between the bottom plane of femur and hip joint. Figure 5.6 illustrates medial 
proximal tibial angle and lateral distal femoral angle on a radiograph. 
Week 0 
6 naive rabbits 
Create growth plate injury 
(12 legs) 
Week 3 
Remove boney bar 
Insert no scaffold 
(2 legs) 
Week 3 
Remove boney bar 
Insert blank scaffold 
(3 legs) 
 
Week 3 
Remove boney bar 
Insert IGF-I plasmid 
encapsulated 
scaffold 
(3 legs) 
Week 3 
Remove boney bar 
Insert IGF-I plasmid 
encapsulated and 
freeze-dried scaffold 
(3 legs) 
Week 11 
Euthanize animals 
Morphometry and histology 
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Figure 5.6 Medial proximal tibial angle and lateral distal femoral angle illustrated on a 
rabbit lower limb radiograph 
 
5.2.4 Histological analysis 
After removal of fibulae, upper half of tibiae were cut sagittally or coronally and 
fixed in 10% buffered formalin for 2 weeks. These samples were then decalcified in 10% 
nitric acid for 4 days for histological staining. Decalcified samples were cut into two 
halves in the coronal plane into anterior and posterior proximal tibiae. Each half was 
embedded in paraffin and cut into 10 micron sagittal or coronal sections using a 
microtome (Finesse ME+). Sections were stained using hematoxylin and eosin by 
deparaffinising in xylene, hydrating through graded alcohol series, immersing in 
hematoxylin for 2 minutes and eosin for 30 seconds, followed by dehydration in alcohol 
series and xylene. Sections stained with safranin-O and acid-fast green were first 
deparaffinised in xylene, hydrated in graded alcohol series, and then immersed in acid-
fast green for 5 minutes and safranin-O for 5 minutes. These sections were then 
dehydrated using graded alcohol series and xylene. Slides were coverslipped using 
Permount SP15-500 (Fisher Scientific). Stained sections were visualized and 
photographed using a Nikon Eclipse E600 microscope (Nikon) attached to a Nikon DN 
100 digital camera (Nikon). 
 
MPTA 
LDFA 
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5.2.5 Statistical analysis 
Statistical analysis was done using SAS 9.1 NC software. ANOVA was used to find 
statistical difference in morphometric parameters between treatment groups. Tukey-
Kramer multiple comparison test was used post-hoc. Sample size calculation was done 
using nQuery Advisor software with 80% power. 
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5.3 RESULTS 
 
5.3.1 Angular measurements 
Figure 5.7 shows the lower hind limbs of an 8 weeks old rabbit prior to injury to 
growth plate (naive). Medial proximal tibial angle and distal lateral femoral angle of 
naive rabbits were measured to calculate how much of varus (inward angulation of limbs) 
occurred as a result of growth plate arrest, and how much varus was corrected after 
implantation of various scaffolds. The medial proximal tibial angles in this particular case 
were 84.64° (right) and 90.58° (left). The lateral distal femoral angles were 96.59° (right) 
and 100.58° (left). 
 
Figure 5.7 Radiograph of lower hind limbs of an 8 weeks old naive rabbit 
 
Figure 5.8 shows the hind limbs after the growth plate arrest was created by 
removing the medial growth plate and allowing the boney bar to form. Note the varus 
created bilaterally. The medial proximal tibial angles decreased to 74.80° (right) and 
83.39° (left), confirming varus in both legs. The lateral distal femoral angles were 96.36° 
(right) and 99.55° (left). 
 97 
 
Figure 5.8 Radiograph of rabbit lower hind limbs 3 weeks after surgery to remove medial 
tibial growth plate, with resultant boney bars 
 
The varus was improved after implantation of scaffolds to remove the boney bars, 
as seen in Figure 5.9. Figure 5.9 shows the hind limbs 8 weeks after a blank hydrophilic 
scaffold was implanted into the right tibia and IGF-I DNA freeze-dried scaffold was 
implanted into the left tibia. The medial proximal tibial angles increased to 78.68° (right) 
and 85.40° (left). 
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Figure 5.9 Radiograph of rabbit lower hind limbs 8 weeks after a blank hydrophilic 
PLGA scaffold was implanted in the right tibia, and IGF-I plasmid freeze-dried and 
encapsulated scaffold was implanted in the left tibia to replace boney bars 
 
Medial proximal tibial angle and lateral distal femoral angles were measured from 
the radiographs for each limb at the start of the study, 3 weeks after the first surgery, and 
8 weeks after the second surgery to study the effect of treatment on correction of angular 
deformity (varus). The results are shown in Figures 5.10 and 5.11. Figure 5.10 shows the 
medial proximal tibial angle for all 4 treatment groups at the start of the study, 3 weeks 
and 11 weeks after the physeal injury. This angle decreased for all treatment groups from 
the start of the study to 3 weeks after physeal injury, confirming formation of boney bar, 
and the success of the physeal injury model. Eight weeks after implantation surgery, the 
MPTA decreased further in all treatment groups, including the group that did not receive 
any implants. The lowest MPTA angle (highest varus) was seen in the no implant group, 
with an average value of 65.19°. The average MPTA for IGF-I plasmid encapsulated 
scaffold treated group was 70.2°, IGF-I plasmid freeze dried scaffold treated group was 
73.11° and blank scaffold treated group was 76.75°. There was no statistical difference in 
MPTA between any treatment groups at any particular time point (p-value > 0.05). 
MPTA for all treatment groups were significantly lower at the 11 weeks time point 
compared to the corresponding MPTA at start of the study (p-value < 0.05). MPTA for 
all treatment groups except “no scaffold” group were significantly lower at the 3 weeks 
time point compared to the corresponding MPTA at the start of the study (p-value < 
0.05). A sample size of 92/treatment group is needed for getting p-value <0.05 with a 
power of 80%. 
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Figure 5.10 Medial proximal tibial angle at start of study, 3 weeks after growth plate 
injury and 8 weeks after implantation of scaffold 
 
Figure 5.11 shows the lateral distal femoral angle for all 4 treatment groups at the 
start of the study, 3 weeks and 11 weeks after the physeal injury. There was no 
statistically significant difference in LDFA between any treatment groups at any 
particular time point (p-value > 0.05). 
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Figure 5.11 Lateral distal femoral angle at start of study, 3 weeks after growth 
plate injury and 8 weeks after implantation of scaffold 
 
5.3.2 Tibia and fibula length measurements 
Medial tibial length was compared across treatment groups to analyze the effect 
of treatment on restoration of medial tibial growth. The results can be seen in Figure 5.12. 
The average length of medial tibia was 94.49 mm for legs implanted with IGF-I DNA 
encapsulated scaffolds. The average medial tibial lengths were 90.87 mm, 91.64 mm and 
91.52 mm for legs implanted with IGF-I DNA freeze dried scaffolds, blank scaffolds, and 
no scaffolds, respectively. Although medial tibial length was highest in the group that 
received IGF-I DNA encapsulated scaffolds, there was no significant difference in the 
length of medial tibia between treatment groups (p-value > 0.05). A sample size of 
31/group is needed for getting p-value < 0.05 with a power of 80%. 
Figure 5.13 shows the difference in length between lateral and medial tibia for 
each treatment group. This is an indicator of how much growth arrest was present in each 
limb because of the physeal damage/regeneration on the medial tibia. The mean 
difference in lateral and medial tibial length was 9.55 mm for IGF-I DNA encapsulated 
scaffold group, 8.49 mm for IGF-I DNA freeze dried scaffold group, 10.48 mm for blank 
scaffold group and 8.525 mm for the group that received no implants. There was no 
statistical difference in intra-tibial length inequality between the treatment groups (p-
value > 0.05). 
Width of the fibula at mid shaft was measured to look for signs of remodeling in 
fibula in response to the changes in tibia. The results can be seen in Figure 5.14. 
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Figure 5.12 Medial tibial length 8 weeks after removal of boney bar and implantation of 
scaffolds 
 
0
2
4
6
8
10
12
14
16
Encapsulated Freeze-dried Blanks No scaffold
Le
ng
th
 (m
m
)
 
Figure 5.13 Lateral-medial tibial length 8 weeks after removal of boney bar and 
implantation of scaffolds 
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Figure 5.14 Width of fibula at mid-shaft 8 weeks after implantation of scaffolds in tibia 
 
The average width of fibula was 2.58 mm, 2.69 mm, 2.4 mm, and 2.645 mm for 
IGF-I DNA encapsulated scaffolds, IGF-I DNA freeze dried scaffolds, blank scaffolds 
and no scaffold implantation, respectively. There was no significant difference in the 
width of fibula across treatment groups (p-value > 0.05). 
5.3.3 Histology 
 
5.3.3.1 No scaffold implantation 
Figure 5.15 shows rabbit tibia cut in coronal plane 8 weeks after boney bar was 
removed and no scaffold was implanted. Remnant of growth plate can be seen in the 
lateral side, and bone has reformed in the region where the boney bar was removed in the 
medial side (arrow). 
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Figure 5.15 H&E stained coronal section of a rabbit medial proximal tibia 8 weeks after 
removal of boney bar with no scaffold implantation. Scale bar is 2 mm. Arrow indicates 
reformed bone. M and L denote medial and lateral 
 
5.3.3.2 Blank scaffolds 
Figure 5.16 shows an H&E stained proximal tibia, cut in coronal plane, 2 weeks 
after implantation of blank PLGA scaffold. Note the cartilaginous tissue seen in blue. The 
bulk of the newly formed tissue is towards the posterior of the section, where the scaffold 
was implanted. Figures 5.17 and 5.18 are higher magnifications from the same section. 
Figure 5.17 shows chondrocytes growing out of the growth plate (arrow). Note the nests 
of chondrocytes seen in Figure 5.18 (arrow).  
 
M L 
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Figure 5.16 H&E stained coronal section of rabbit proximal tibia 2 weeks after 
implantation of blank PLGA scaffold. Scale bar is 2 mm. M and L denote medial and 
lateral 
Implant 
site 
M L 
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Figure 5.17 H&E stained section of rabbit proximal tibia 2 weeks after implantation of 
PLGA scaffold. Scale bar is 1mm. Arrow indicates growth plate 
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Figure 5.18 H&E stained section of rabbit proximal tibia 2 weeks after implantation of 
PLGA scaffold. Scale bar is 200 microns. Arrow indicates nest of chondrocyte 
 
Figures 5.19 and 5.20 show sagittal sections of the medial proximal tibia of a 
rabbit 8 weeks after implantation of a hydrophilic scaffold. Note the cartilaginous region 
growing out of the remnants of growth plate in Figure 5.19. This cartilaginous region 8 
weeks after implantation is significantly smaller compared to the 2 weeks time point seen 
in Figure 5.16. Figure 5.20 is a higher magnification of the same section that shows 
hypertrophic chondrocytes and nests of chondrocytes. 
 
Figure 5.19 H&E stained sagittal section of rabbit medial proximal tibia 8 weeks after 
implantation of PLGA scaffold. Scale bar is 2 mm 
Implant 
site 
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Figure 5.20 H&E stained section of rabbit medial proximal tibia 8 weeks after 
implantation of PLGA scaffold. Scale bar is 1 mm 
 
Figures 5.21 and 5.22 are sagittal sections of medial proximal tibia from a rabbit 
16 weeks after implantation of a hydrophilic PLGA scaffold. Notice the short band of 
growth plate remnant (arrow). No cartilaginous tissue is seen at the implant site on the 
other end. Figure 5.22 is a higher magnification of the same section showing the distorted 
remnant of growth plate. The distortion was caused by a collapse of tibial plateau after 
creation of growth plate injury. 
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Figure 5.21 H&E stained sagittal section of rabbit medial proximal tibia 16 weeks after 
implantation of PLGA scaffold. Scale bar is 2 mm 
 
 
Figure 5.22 H&E stained section of rabbit medial proximal tibia 16 weeks after 
implantation of PLGA scaffold. Scale bar is 1 mm 
 
Implant site 
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5.3.3.3 IGF-I plasmid-releasing scaffolds 
Figure 5.23 shows rabbit tibia cut in coronal plane 8 weeks after implantation of 
an IGF-I plasmid encapsulated scaffold. The remnant of growth plate can be seen to the 
right side of the image, while cartilaginous growth can be seen to the left side, where the 
scaffold was implanted (arrow). Figure 5.24 is a higher magnification of the cartilaginous 
region, that shows nests of chondrocytes. Figure 5.25 of the same region shows nests of 
chondrocytes, as well as growth-plate-like stacks of chondrocytes. 
 
 
Figure 5.23 H&E stained coronal section of rabbit medial proximal tibia 8 weeks after 
implantation of an IGF-I plasmid encapsulated scaffold. Scale bar is 2 mm. Arrow 
indicates new cartilage. M and L denote medial and lateral 
Implant 
site 
M L 
 110 
 
Figure 5.24 H&E stained section of rabbit medial proximal tibia 8 weeks after 
implantation of an IGF-I plasmid encapsulated scaffold. Scale bar is 1 mm 
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Figure 5.25 H&E stained section of rabbit medial proximal tibia 8 weeks after 
implantation of an IGF-I plasmid encapsulated scaffold. Scale bar is 200 microns 
 
Figures 5.26 and 5.27 are safranin-O and fast-green stained sections of a rabbit 
medial proximal tibia 8 weeks after implantation of an IGF-I plasmid encapsulated 
scaffold. Intense staining is visible in the region where the scaffold was implanted. Nests 
and stacks of chondrocytes are visible in Figure 5.27 (arrows). 
 
 
Figure 5.26 Safranin-O stained section of rabbit medial proximal tibia 8 weeks after 
implantation of an IGF-I plasmid encapsulated scaffold. Scale bar is 1 mm 
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Figure 5.27 Safranin-O stained section of rabbit medial proximal tibia 8 weeks after 
implantation of an IGF-I plasmid encapsulated scaffold. Scale bar is 200 microns. Arrows 
indicates stacks of chondrocytes 
 
Figure 5.28 shows rabbit tibia cut in coronal plane 8 weeks after implantation of 
an IGF-I plasmid freeze-dried scaffold. The remnant of growth plate can be seen to the 
right side of the image, while cartilaginous growth can be seen to the left side, where the 
scaffold was implanted. Figures 5.29 and 5.30 are higher magnifications of the same 
section that show hypertrophic chondrocytes as well as nests of chondrocytes in the 
implant region. Figure 5.31 is safranin-O and fast green stained section of cartilage 
formed after implantation of IGF-I plasmid freeze-dried scaffold. Intense staining for 
GAG is visible. 
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Figure 5.28 H&E stained coronal section of a rabbit medial proximal tibia 8 weeks after 
implantation of IGF-I plasmid freeze-dried scaffold. Scale bar is 2 mm. M and L denote 
medial and lateral 
 
 
Figure 5.29 H&E stained section of a rabbit medial proximal tibia 8 weeks after 
implantation of IGF-I plasmid freeze-dried scaffold. Scale bar is 1 mm 
Implant site 
M 
L 
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Figure 5.30 H&E stained section of a rabbit medial proximal tibia 8 weeks after 
implantation of IGF-I plasmid freeze-dried scaffold. Scale bar is 200 microns 
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Figure 5.31 Safranin-O stained section of a rabbit medial proximal tibia 8 weeks after 
implantation of IGF-I plasmid freeze-dried scaffold. Scale bar is 200 microns 
 
Figure 5.32 a shows rabbit tibia cut in coronal plane 8 weeks after implantation of 
a blank scaffold. The remnant of growth plate can be seen to the right side of the image, 
while no cartilage is seen to the left side, where the scaffold was implanted.  
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Figure 5.32 H&E stained coronal section of a rabbit medial proximal tibia 8 weeks after 
implantation of blank scaffold. Scale bar is 2 mm. M and L denote medial and lateral 
 
 
Implant 
site 
M L 
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5.4 DISCUSSION 
 
5.4.1 Effect of treatment on correction of varus angular deformity 
Growth plate injuries in children often heal with the formation of boney bars, and 
lead to life lasting consequences of varus deformity and limb length discrepancies unless 
surgically corrected. Polymer scaffolds have been used for the treatment of physeal injury 
in different animal models with varying degrees of success by several research groups. 
Implantation of a chitin fibrin mesh with pre-seeded mesenchymal stem cells in a rabbit 
model of physeal injury resulted in significantly lower tibiofemoral angle and limb length 
discrepancy at 16 weeks after implantation (Li, 2004). Implantation of mesenchymal 
stem cells embedded in agarose gel in a rabbit physeal injury model resulted in some 
correction of tibiofemoral angle and limb length discrepancy (Chen, 2003). Implantation 
of atelocollagen scaffolds with autologous chondrocytes into a rabbit physeal injury 
model resulted in significantly lower angular deformity, as determined by MPTA, 
compared to untreated defects and defects implanted with fat (Tobita, 2002). 
To our knowledge, nobody has succeeded in showing significant morphometric 
improvements 8 weeks after treatment in an animal model without the use of cell-
embedded scaffolds. In our study, implantation of IGF-I DNA freeze-dried PLGA 
scaffold after removal of boney bar resulted in a medial proximal tibial angle of 85.4º 
compared to 78.68º when a blank scaffold was inserted. Medial proximal tibial angle for 
legs with no scaffold implantation were between 69.54º and 62.87º, for IGF-I DNA 
encapsulated scaffolds between 60.78º and 79.56º, IGF-I DNA freeze-dried scaffolds 
between 65.60º and 85.40º, and blank scaffolds between 65.6º and 85.98º. It was 
observed that all treatment groups had at least one animal with significantly lesser 
residual angular deformity compared to the group that received no scaffold implants. 
However, as evident in Figures 3.10 and 3.11, when comparing the different treatment 
groups, no statistical difference was seen in either the medial proximal tibial angle or the 
lateral distal femoral angle. There are several contributing factors that might have led to 
this result. 
All our angle measurements were done manually using low quality fluorographs, 
which increases the operator variability of measurements because of speculating the 
position of anatomical landmarks. We did not have access to a regular X-Ray machine to 
capture high quality radiographs until the end of this study, which precluded us from 
making better measurements of medial proximal tibial angles and lateral distal femoral 
angles. 
Close examination of Figure 3.10 will reveal that the mean medial proximal tibial 
angle for the group that received no scaffolds was lower than the mean medial proximal 
tibial angle for all the other treatment groups. However this difference was not 
statistically significant. Our experimental design with three legs in each treatment group 
might have masked any benefit from treatment because of the low number of samples per 
group and the high variability between samples. Although variability in our angle 
measurements is comparable to what other similar studies have shown, the number of 
samples per group were much higher at 11 legs/treatment group (Lee, 2002; Planka, 
2008), and 24 legs/treatment group (Li, 2004). Lateral distal femoral angle, did not show 
any statistical difference between treatment groups as expected, since no interventions 
were done on femurs. Absence of any significant differences in lateral distal femoral 
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angle also indicates that the varus was caused solely by the intra-limb length inequality of 
tibia. 
 
5.4.2 Effect of treatment on correction of limb length inequality 
We examined medial tibial lengths and the difference in lateral and medial length 
for each tibia to see the effect of treatment on correcting intra-limb and inter-limb length 
inequalities. When fat, silastic spacer, and physeal transplants were used to treat a rabbit 
model of physeal injury, no significant differences in lateral-medial tibial heights were 
seen compared to no treatment 8 weeks after resection of boney bars (Lee, 1993). 
Implantation of 0.3% agarose with autologous chondrocytes in a rabbit physeal injury 
model resulted in less difference between lateral and medial tibial lengths, compared to 
groups that received 0.3% agarose alone or no treatment (Lee, 1998). But it is not known 
if the difference was statistically significant. The results were similar when 0.3% agarose 
with MSCs were implanted to treat physeal injury, but the difference was still statistically 
insignificant (Chen, 2003). Hyaluronate-collagen scaffolds seeded with autologous MSCs 
were implanted into a rabbit femur physeal injury model, resulting in significantly longer 
femurs at 16 weeks compared to untreated contralateral femurs (Planka, 2008). Lateral-
medial tibial length differences were significantly lower compared to untreated defects 52 
weeks after implantation of atelocollagen gels with chondrocytes into physeal defects, but 
the difference was not significant at the 8 week time point after implantation (Tobita, 
2002). These studies illustrate the lack of consistent positive results in the treatment of 
physeal injury animal models using various approaches.  
In our study, we saw the highest medial tibial length in the group that was treated 
with IGF-I DNA encapsulated scaffolds. But, the difference in medial tibial length 
between treatment groups was not significant. Insufficient number of samples/group 
might have contributed to this result. Angular and length deformity resulting from an 
injured growth plate is progressive until the animal reaches skeletal maturity (Salter, 
1963). This phenomenon can significantly influence the inference from interventions to 
treat growth plate injury, depending on the time point at which the morphometric 
measurements are taken relative to the age of skeletal maturity of the experimental 
animal. When comparing the results at different time points after implantation of 
atelocollagen gel with autologous chondrocytes, it was seen that the differences in 
angular deformity was significant at 24 weeks, but not 8 weeks after implantation of the 
scaffolds (Tobita, 2002). Similarly, limb length discrepancies for the treated and 
untreated groups increased at different rates, making the differences significant at 24 
weeks, but not 8 weeks after implantation (Tobita, 2002). 
New Zealand white rabbits reach skeletal maturity at 28 weeks, and reach adult 
lengths by 34 weeks of age (Masoud, 1986). Their mean tibial length reach 94% of the 
adult value by 16 weeks of age, with most tibial growth complete between 26 and 28 
weeks (Masoud, 1986). More importantly, the mean age at proxibal tibial growth plate 
fusion was 25 weeks (Masoud, 1986). Thus, the rabbits used in our study would have had 
6 to 11 weeks of tibial growth left after the time point at the experiment was terminated. 
Continued tibial growth during this time would have amplified the small difference in 
angular deformity and length difference between treatment groups that we now see at 8 
weeks after implantation, and made them significant. This warrants further studies in 
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which morphometric measurements are made at multiple time points without sacrificing 
the animals, and continuing the study until the animals reach skeletal maturity. 
We measured width of fibula to look for signs of remodeling due to alterations in 
load distribution in the lower limb that can happen because of changes in morphology of 
tibia. We did not see any patterns in the width of fibula, or any statistically significant 
differences between treatment groups. This can again be due to insufficient time for any 
such remodelling to have developed, or because of the quadruped nature of rabbits which 
reduces the load on hind limbs compared to bipedal animals. 
 
5.4.3 Effect of PLGA scaffold implants on regenerated growth plate 
 
5.4.3.1 No scaffolds and Blank scaffolds 
We saw reformation of bone at the surgery site when no scaffold was implanted 
after removal of the boney bar.  
We saw that cartilage had developed just 2 weeks after implantation in the area 
where a hydrophilic blank scaffold was implanted after resection of boney bar. Nests of 
chondrocytes were also observed. The newly formed cartilage was disorganized, and 
appeared to grow out of the remnants of native growth plate. We did not observe any 
growth plate-like columnar arrangement of chondrocytes in the newly formed cartilage. It 
is not surprising that we did not see any organized structure to the newly formed cartilage 
since the implanted scaffold did not have any chondrogenic growth factors to specifically 
stimulate the formation of a new growth plate. Newly formed cartilage after implantation 
of hyaluronate-collagen-MSC scaffolds to treat physeal injury in rabbits did not show any 
growth plate organization (Planka, 2008). But implantation of 0.3% agarose gel with 
MSC into a physeal defect resulted in physis-like columnar arrangement of chondrocytes 
in the newly formed physis (Chen, 2003). Growth plate-like columnar arrangement of 
chondrocytes was also seen when 0.3% agarose with embedded chondrocytes was used to 
treat physeal defects in rabbits (Lee, 1998). 
The interpositional material used after removal of boney bar must remain in its 
original position, and in contact with metaphysis and epiphysis to prevent the reformation 
of a boney bar (Khoshhal, 2005). Mass loss studies using our scaffolds have shown 
previously that about 80% of their mass is lost within 4 weeks of immersion in PBS. The 
results that we saw from histological analysis of implant site also indicate that the 
implanted scaffold was quickly replaced by the newly formed tissue. We were unable to 
see remnants of our scaffold even at 2 weeks after implantation. PLGA has been shown 
to degrade faster in acidic environments, as would be the case at the implantation site. 
Decreased pH and cellular activity would have accelerated the degradation rate of our 
scaffolds after they were implanted in the rabbits. Scaffolds made of PLGA with a 
molecular weight of 110,000 degraded to half their volumes after implanted 
subcutaneously in mice for 8 weeks (Jeon, 2007). In contrast, the scaffolds used in our 
study had a molecular weight of 10,000. 
 
5.4.3.2 IGF-I plasmid-releasing scaffolds 
We were able to see several nests of chondrocytes as well as columnar 
arrangement of chondrocytes in the newly formed cartilage 8 weeks after removal of 
boney bar and implantation of an IGF-I encapsulated scaffold. The newly formed growth-
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plate like structure was thicker than the remnant of the intact growth plate, and covered 
only a quarter of the area of the boney bar. It also lacked the level of organization seen in 
native growth plate cartilage. Nevertheless, this is the first time that anyone has shown 
growth-plate like columnar arrangement in regenerated growth plate without 
transplanting progenitor cells into the defect. 
Implantation of IGF-I plasmid freeze-dried scaffold after removal of boney bar 
resulted in formation of cartilage with some nests of chondrocytes. The quality of 
cartilage was inferior to the one seen after implantation of IGF-I plasmid encapsulated 
scaffolds, as we did not see any growth plate-like stacks of chondrocytes in this case. It is 
possible that the cells could not be effectively transfected with the released PEI:DNA 
complexes from the scaffold as PEI:DNA complexes have been shown to aggregate at 
high concentrations (Huang, 2003).  
We saw a decrease in the amount of cartilage at the implant site from 2 to 8 to 16 
weeks after blank scaffolds were implanted. The area of newly formed cartilage at 8 
weeks was much smaller compared to the cartilaginous area at 2 weeks after 
implantation. At 16 weeks, almost no cartilaginous region was seen, having been 
completely replaced by trabecular bone. Even when IGF-I plasmid releasing scaffolds 
were implanted, very little cartilaginous tissue was seen at the implant site 8 weeks after 
the scaffold was implanted. This progressive decrease in the amount of cartilage at the 
implant site might have been because of the normal process of endochondral ossification 
that progressively replaced newly formed cartilage with trabecular bone. Similar 
progressive decrease in the amount of newly formed cartilage was seen when 
atelocollagen gel with chondrocytes were implanted to treat physeal injury (Tobita, 
2002). The amount of newly synthesized cartilage on PLGA scaffolds decreased at 12 
weeks compared to 8 weeks after subcutaneous implantation in mice, and was almost 
completely absent at 16 weeks (Jeon, 2007). Even when adIGF-I injected muscle was 
implanted after removal of boney bar in rabbits, the resultant cartilage lost its columnar 
appearance by 12 weeks compared to 8 weeks (Lee, 2002). 
In order for any intervention to be effective in treating angular and length 
discrepancies after removal of boney bars, it should be able to maintain the newly formed 
growth plate/cartilage until such time as the physiological fusion of native growth plate. 
In fact, reformation of boney bars or secondary tethers after removal of boney bars was 
the most common mechanism of treatment failure in human subjects (Hasler, 2002).  
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5.5 CONCLUSION 
 
Removal of boney bar and implantation of IGF-I plasmid-releasing PLGA 
scaffolds in an animal model of growth plate injury resulted in some improvement of 
MPTA compared to no scaffold implantation. Medial tibial length was also higher for the 
scaffold implanted group compared to no scaffold implantation after removal of boney 
bars. These differences were not statistically significant partly because of insufficient 
number of animals in each experimental group. Histological analysis of the newly 
developed cartilage showed growth plate-like columnar arrangement of chondrocytes in 
an animal that received IGF-I plasmid encapsulated scaffold. Although the newly formed 
cartilage lacked the level of organization seen in native growth plate, we are the first ones 
to report the regeneration of growth plate-like structure without the use of stem cells in an 
animal model of growth plate injury. Histological evaluation suggests that, although we 
were successful in creating growth plate-like structure using our scaffolds after removal 
of boney bars, the benefits were quickly lost as the newly formed cartilage was replaced 
by trabecular bone. Future approaches to regenerate the growth plate might benefit from 
the sustained presence of IGF-I at the injury site, and scaffolds made of materials that last 
longer in vivo, and thus sustain the newly formed growth plate until the animals reach 
skeletal maturity.  
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6. SUMMARY AND CONCLUSIONS 
 
Controlled release of naked and PEI:DNA complexes was achieved from porous 
PLGA scaffolds. PEI affected release of complexes from PLGA scaffolds, as PEI:DNA 
complexes were released at a lower rate compared to naked DNA from low molecular 
weight and high molecular weight PLGA scaffolds, as well as hydrophilic and 
hydrophobic PLGA scaffolds. Hydrophilicity and molecular weight of PLGA had effects 
on the release profiles of both naked DNA and PEI:DNA complexes from the scaffolds, 
as evidenced by later peak naked DNA and PEI:DNA release with increasing 
hydrophilicity and molecular weight. Compressive modulus and ultimate strength for 
high molecular weight PLGA scaffolds were significantly higher than low molecular 
weight PLGA scaffolds. Porous scaffolds made of PLGA with the right hydrophobicity 
and molecular weight will allow us to tailor degradation profiles and mechanical 
properties of these scaffolds for controlled delivery of naked and condensed plasmid 
DNA in tissue engineering applications. 
Low molecular weight hydrophilic PLGA scaffolds supported the growth and 
differentiation of mesenchymal multipotent D1 cells, chondrocytes and bone marrow 
cells in vitro. Suspension of cells in fibrin prior to seeding resulted in significant 
differences in total GAG and GAG/DNA contents between IGF-I treated and control 
groups for mesenchymal stem cells, bone marrow cells and chondrocytes, whereas the 
differences were not significant when cultured on scaffolds without fibrin. This proved 
that fibrin was critical in the differentiation of the cells into chondrogenic phenotype, 
probably by retaining seeded cells within the scaffold and thus increasing cell density, as 
well as encapsulating the cells in a three dimensional environment. Culturing BMCs on 
IGF-I plasmid encapsulated scaffolds resulted in elevated expression of rhIGF-I 
compared to blank and IGF-I plasmid freeze-dried scaffolds. Although the amount of 
IGF-I produced was not statistically significant compared to controls, sample size 
calculations suggested that increasing the number of samples to 4/group can make the 
difference statistically significant. Bone marrow cells cultured on the IGF-I plasmid 
encapsulated scaffolds showed the highest DNA content among all the groups. Total 
GAG was higher for all plasmid-releasing scaffolds compared to the blank scaffolds, but 
these differences were not statistically significant. Low exposure to IGF-I released from 
transfected cells might have been the reason for the inability to observe significant 
chondrocytic differentiation in bone marrow cells seeded on IGF-I plasmid-releasing 
scaffolds. Using scaffolds made from higher molecular weight hydrophilic PLGA to 
culture cells, along with increasing the amount of IGF-I secreted can increase the 
exposure of cells to IGF-I, and might result in successful chondrogenesis using bone 
marrow progenitor cells. 
Removal of boney bar and implantation of IGF-I plasmid-releasing PLGA 
scaffolds in an animal model of growth plate injury resulted in some improvement of 
MPTA compared to no scaffold implantation. Medial tibial length was also higher for the 
scaffold implanted group compared to no scaffold implantation after removal of boney 
bars. These differences were not statistically significant partly because of insufficient 
number of animals in each experimental group. Histological analysis of the newly 
developed cartilage showed growth plate-like columnar arrangement of chondrocytes in 
an animal that received IGF-I plasmid encapsulated scaffold, even though the level of 
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organization of this newly formed cartilage was inferior to that of native growth plate. 
We are the first ones to report the regeneration of growth plate-like structure without the 
use of stem cells in an animal model of growth plate injury. Histological evaluation 
suggests that although we were successful in creating growth plate-like structure using 
our scaffolds after removal of boney bars, the benefits were quickly lost as the newly 
formed cartilage was replaced by trabecular bone. Future approaches to regenerate the 
growth plate might benefit from the sustained presence of IGF-I at the injury site, and 
scaffolds made of higher molecular weight PLGA, and thus sustain the newly formed 
growth plate until the animals reach skeletal maturity. 
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